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ix
The attention of the world is currently fixed on three countries in West 
Africa, and understandably so. Emerging infectious diseases such as 
Ebola pose a serious threat not just to the societies and the men, women, 
and children in the immediate vicinity of an outbreak, but to countless 
others around the world owing to globalization.
At the same time, it remains the case that the gravest health threats 
facing low- and middle-income countries are less the obscure viruses 
or ancient plagues that dominate the news cycle and international relief 
efforts so much as diseases we understand and could address but too 
often fail to combat.
Once thought to be challenges for affluent countries alone, car-
diovascular diseases, cancer, diabetes, and other noncommunicable 
diseases (NCDs) are now the leading cause of death and disability in 
developing countries. In 2013, these diseases killed eight million people 
before their sixtieth birthdays in these countries. The chronic nature of 
NCDs means patients may be sick for many years and require exten-
sive medical care. The economic costs, in terms of both immediate 
health-care costs and lost productivity, are high and rising in low- and 
middle-income countries, threatening their continued development 
and prosperity. 
Possibly because NCDs constitute a gathering rather than a dra-
matic or imminent crisis, the international response has been woefully 
inadequate. The United States has no dedicated programs or budget 
for addressing NCDs globally. Despite the efforts of the World Health 
Organization and the United Nations to elevate the priority of these 
diseases, aid for NCDs represented just 1.2 percent of total develop-
ment assistance for global health in 2011. The urgency of this situation 
led the Council on Foreign Relations (CFR) to convene an Independent 
Task Force on Noncommunicable Diseases—its first ever devoted to a 
global health matter. 
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The report begins by examining NCDs in developing countries and 
the factors driving their increasing prevalence. The analysis reveals 
that NCDs are rising faster, affecting younger populations, and having 
worse health and economic outcomes than seen in developed countries. 
This growing epidemic, the report says, is not merely the unfortunate 
byproduct of higher incomes and declining infectious disease rates. 
The report credits the confluence of several dramatic trends for driving 
the increase in NCDs: unprecedented rates of urbanization, global inte-
gration of consumer markets, and advances in longevity in still-poor 
countries that lack sufficient health systems to adjust.
The report also assesses the case for increased U.S. focus on NCDs. 
That assessment includes an examination of the countries that receive 
significant U.S. health assistance and finds that premature burden of 
death and disability in many of these countries is heavily NCD-related. 
The Task Force concludes that deeper U.S. involvement on NCDs is 
needed to ensure the continued effectiveness and credibility of U.S. 
global health programs in these countries, to advance U.S. trade with 
emerging economies, and to build institutional capacity in states of U.S. 
strategic concern.
There is much the United States can do to help developing countries 
meet the NCD challenge at relatively modest cost. U.S. efforts should 
focus on the specific NCDs and risk factors that are especially preva-
lent among the working-age poor in developing countries and for which 
there are existing low-cost interventions that can leverage current U.S. 
global health programs. Based on those criteria, the Task Force offers 
short-, medium-, and long-term recommendations for action. These 
range from prevention of cardiovascular disease to helping countries 
establish effective tobacco controls. 
The report concludes with a call for the United States to take two 
immediate steps. First, the Task Force urges the U.S. government to 
undertake a serious examination of its global health programs and con-
sider expanding their mandate. Second, the Task Force recommends 
that the United States convene other leading actors and potential 
partners on addressing NCDs —national governments, international 
institutions, philanthropic foundations, nongovernmental organi-
zations, and private companies—to develop a well-prioritized and 
sustainable plan for collective action on NCDs in low- and middle-
income countries.
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3Executive Summary
The biggest global health crisis in low- and middle-income countries 
is not the one you might think. It is not the exotic parasites, bacterial 
blights, or obscure tropical viruses that have long occupied interna-
tional health initiatives and media attention. It is cancer, cardiovascular 
disease, diabetes, and other noncommunicable diseases (NCDs), which 
killed more than eight million people before their sixtieth birthdays in 
low- and middle-income countries in 2013 alone. Unless urgent action 
is taken, the NCD crisis emerging in developing countries will worsen 
and become harder to address with each passing year. 
The rise of NCDs in low- and middle-income countries is not merely 
the byproduct of success—increasing incomes, reductions in infec-
tious diseases such as HIV/AIDS, or greater adoption of unhealthy 
western lifestyles. Recent improvements in life expectancy explain why 
more people in developing countries get NCDs. They do not, however, 
explain why so many people in these countries are developing NCDs so 
much younger and with such worse outcomes than in wealthier nations. 
Rates of obesity, consumption of fatty foods, and physical inactivity 
are rising in low- and middle-income countries, but they remain much 
lower than in most high-income countries. Premature death and dis-
ability from NCDs are increasingly associated with poverty in emerg-
ing nations, just as they are in wealthier countries. 
The factors fueling the emergence of NCDs are the combination of 
dramatic changes in urbanization, global trade and consumer markets, 
and longevity that occurred over decades in wealthy nations but are 
happening much faster in still-poor countries. These changes are out-
pacing the ability of developing-country governments to establish the 
health and regulatory systems necessary to adjust. With these trends 
expected to persist or accelerate, the toll of NCDs on working-age pop-
ulations will increase in these countries (Figure 1).
4 The Emerging Global Health Crisis
U.S. interests will be affected by the rise of NCDs in low- and mid-
dle-income countries because of their human, economic, and strategic 
consequences. More patients will get sick, suffer longer, require more 
medical care, and die young. Given the scale of these trends, the results 
will reverberate. At the household level, it will mean less income, cata-
strophic health expenditures, and potential impoverishment. At the 
national level, it will mean lower productivity and competitiveness, 
higher health and welfare expenditures, and a potential missed oppor-
tunity for the demographic dividend that lifted the fortunes of many 
higher-income countries. At the global level, the World Economic 
Forum projects that the NCD epidemic will inflict $21.3 trillion in 
losses in developing countries over the next two decades—a cost nearly 
equal to the total aggregate economic output ($24.5 trillion) of these 
countries in 2013. These economic consequences will undercut poten-
tial U.S. trade partners and allies, and may reduce domestic support for 
foreign governments of strategic interest to the United States.
This outcome is not inevitable. Despite much higher rates of obesity 
and physical inactivity, premature death and disability from NCDs have 
FIGURE 1:  PREMATURE (UNDER AGE SI x T y) DE AT HS FROM NCDS
Underlying Data Source: Institute for Health Metrics and Evaluation, Global Burden of Disease Study 2013.1
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declined dramatically in the United States and other high-income coun-
tries. The difference? Mostly cheap and effective prevention, manage-
ment, and treatment tools and policies that are not widely implemented 
in developing countries, but could be by using well-established global 
health strategies. Yet the international community has struggled to act.
The urgency of this situation has led the Council on Foreign Relations 
(CFR) to convene an Independent Task Force on Noncommunicable 
Diseases in Low- and Middle-Income Countries—its first ever devoted 
to a global health matter. The charge of this Task Force is to assess the 
case for greater U.S. engagement on the NCD crisis in developing coun-
tries and recommend a practical and scalable strategy for intervention.
The last time that the world confronted a global health challenge 
that caused such a large number of premature adult deaths and so dis-
proportionately affected low- and middle-income countries was HIV/
AIDS. The United States led the global response to that disease, and the 
world rallied to its side. The U.S. government launched the President’s 
Emergency Plan for AIDS Relief (PEPFAR) and worked with other 
donors and partners to establish the Global Fund to Fight AIDS, Tuber-
culosis, and Malaria. These programs have delivered treatment to mil-
lions, saved many lives, and inspired a dramatic increase in international 
support for addressing other global health challenges from malaria to 
family planning to maternal and child health. It is an accomplishment 
of which every American may feel deeply proud.
This Task Force finds that leadership on the new emerging global 
health crisis of NCDs in low- and middle-income countries is vital to 
U.S. interests—in improved global health, increased trade and devel-
opment, and U.S. standing in the world. The means by which that 
leadership is demonstrated, however, must be different from U.S. inter-
ventions on HIV/AIDS. 
The United States cannot solve the NCD crisis emerging in develop-
ing countries. Determining health priorities and allocating resources in 
the face of this crisis are decisions for national governments. Yet, work-
ing with like-minded partners, the United States can slow the rise of 
this epidemic, lessen its worst effects, and help provide national gov-
ernments with the time and technical assistance needed to tackle this 
emerging crisis sustainably on their own. 
Figure 2 depicts two projections. The first (red line) is the expected 
increase in premature (defined in this report as under age sixty) deaths 
from NCDs in the forty-nine countries where the United States 
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currently has significant global health investments. The second (blue 
line) is the decrease in premature mortality that would occur if those 
countries improved NCD prevention and treatment at the same rate 
that the average high-income country did between 2000 and 2013. The 
difference between those projections is 5,166,984 lives over the next 
eleven years. If this outcome could be achieved or even approached, the 
results would be comparable to other successful U.S.-supported initia-
tives on childhood immunization and HIV.2 
The Task Force recommends that U.S. investments in NCDs focus 
initially on the specific diseases and risk factors that are (a) especially 
prevalent among the working-age poor in developing countries and for 
which (b) effective and low-cost interventions exist that are (c) amena-
ble to collective action and (d) can leverage existing U.S. global health 
programs and platforms. The Task Force applied these criteria to the 
NCDs that are causing large numbers of premature deaths in low- and 
middle-income countries but far fewer in high-income countries. That 
assessment provides the basis for our recommendations in three areas. 
FIGURE 2:  PROJECTED PREMATURE NCD DE AT HS I N FORT y-N I NE 
U.S .  PR IOR I T y COUN TR I E S,  2014–2025
Underlying Data Source: Institute for Health Metrics and Evaluation, Global Burden of Disease Study 2013. 
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■■ Challenges on which U.S. leadership would make a tremendous difference 
now: primary and secondary prevention of cardiovascular disease; 
tobacco control; hepatitis B vaccination to prevent liver cancer; and 
human papillomavirus (HPV) vaccination and screening programs to 
prevent cervical cancer
■■ Challenges on which U.S. leadership would make a tremendous differ-
ence soon: frugal diagnostic and curative care strategies for treatable 
and curable cancers such as leukemia and breast cancer; and better 
diabetes management for low-resource settings
■■ Shared challenges on which U.S. collaboration with developing coun-
tries and the private sector could help: population-based strategies to 
reduce poor diets and nutrition, physical inactivity, and obesity; inte-
gration of mental health into primary care; and low-cost chronic care 
programs and technologies
The recommendation to increase U.S. engagement on NCDs is not 
one to which this Task Force comes lightly. The United States already 
does much to address global health, and its resources are not infinite. 
Yet given strong U.S. interests in addressing the rising NCD epidemic 
in developing countries and the availability of proven, cost-effective 
interventions, our conclusion is unavoidable. The time to act is now.
This report proceeds as follows. Sections one and two examine the 
emerging crisis of NCDs in developing countries and the factors behind 
its rise. Section three assesses U.S. interests in increased engagement 
on NCDs internationally. Section four presents a practical, data-driven 
set of recommendations for that engagement. Each recommendation is 
accompanied by a case for U.S. investment. 
The report concludes with two immediate steps that the United 
States should take. First, the U.S. government should undertake a seri-
ous examination of its global health priorities and spending and act to 
ensure their continued effectiveness in advancing U.S. interests. In the 
forty-nine countries with the most U.S. global health investment, the 
U.S. government spent $44.17 in aid for each year of life lost to disabil-
ity and early death from HIV/AIDS in 2010 (as measured in disability-
adjusted life years, or DALYs), $4.21 per DALY lost to malaria, and 
$1.82 per DALY lost to tuberculosis, but only $0.02 per DALY lost to 
NCDs. If the United States devoted the same resources it spends at 
the lower end of this range—$236 million on tuberculosis in fiscal year 
(FY) 2014—to NCDs, it would go a long way toward implementing the 
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recommendations outlined in this report. The United States should 
consider the potential for additional funds to respond to the changing 
needs of these countries and the feasibility of building on the positive 
legacy of PEPFAR-funded programs by expanding their mandate from 
disease-focused goals to more outcome-oriented measures for improv-
ing health. 
The costs and the burden of action on NCDs should not be borne by 
the United States alone. The second step that the United States should 
take is to convene the leading actors and potential partners for address-
ing NCDs—national governments, intergovernmental and inter-
national institutions, philanthropic foundations, nongovernmental 
organizations (NGOs), and private companies, especially large-scale 
employers operating in heavily affected countries. The purpose of this 
convening should be to develop a practical, well-prioritized, and sus-
tainable plan for collective action on the global health crisis of NCDs in 
low- and middle-income countries.
9When most people in developed countries think of the world’s biggest 
health challenges, they envision a small child in a dusty, rural village suf-
fering from an exotic parasite or bacterial blight. But increasingly, that 
image is wrong. Instead, it is the working-age woman living in an urban 
slum in a low- or middle-income country suffering from cervical cancer, 
or the father of young children dying of a stroke—noncommunicable 
diseases that were once thought to confront wealthy nations alone.3
NCDs are rising fast in low- and middle-income countries (Figure 3). 
As defined by the World Health Organization (WHO), NCDs are a broad 
category of chronic diseases and conditions that cannot themselves be 
The Rising Epidemic of NCDs 
in Low- and Middle-Income Countries
FIGURE 3:  DE AT HS CAUSED By NCDS I N LOW- AND M I DDLE -
I NCOME COUN TR I E S
Data Source: Institute for Health Metrics and Evaluation, Global Burden of Disease Study 2013.
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spread from person to person, although they may be caused by viruses 
or bacteria that can. In developing countries, four NCDs dominate. Car-
diovascular diseases, cancer, and chronic respiratory illnesses cause 80 
percent of the deaths and two-thirds of the disability from NCDs in these 
countries (Figure 4). Rates of diabetes are increasing the fastest, particu-
larly in Central America, Africa, the Middle East, and Oceania. 
Cancer, diabetes, stroke, and these other NCDs long ago became 
a challenge for developed countries as well, but the epidemiological 
transition happening in developing countries differs in speed, scale, 
and consequence. The rise of NCDs in these countries is not simply a 
result of reductions in the plagues and parasites that kill children and 
adolescents.4 Death and disability from NCDs in low- and lower-mid-
dle-income countries is increasing faster than the rate of decline from 
communicable diseases. The trajectories of many NCDs depend on the 
wealth of the country where one lives. The death and disability wrought 
by heart disease, stroke, breast cancer, and other NCDs (measured 
in Table 1 as disability-adjusted life years, or DALYs) are subsiding in 
developed countries but increasing fast in developing countries. 
Data Source: Institute for Health Metrics and Evaluation, Global Burden of Disease Study 2013.
FIGURE 4:  CAUSE OF NCD DE AT HS I N LOW- AND M I DDLE -
I NCOME COUN TR I E S
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NCDs are also arising faster in younger populations in low- and 
middle-income countries than in wealthy states. Most of the death and 
disability from NCDs in emerging countries (as depicted in Figure 5, 
in DALYs) occurs in working-age people (those under the age of sixty). 
In many low-income countries, particularly in Africa, that proportion 
rises to 80 percent or higher. 
NCDs are not only rising faster and in younger populations in low- 
and middle-income countries, they are also yielding worse outcomes 
(Figure 6). NCDs that are preventable or treatable in developed coun-
tries are often death sentences in developing countries. Whereas cer-
vical cancer can largely be prevented in developed countries thanks to 
the HPV vaccine, in sub-Saharan Africa and South Asia it is the lead-
ing cause of death from cancer among women;5 likewise, 90 percent 
of children with leukemia in high-income countries can be cured, but 
90 percent of those with that disease in the world’s twenty-five poorest 
countries die from it.6 Nine out of ten chronic obstructive respiratory 
deaths worldwide occur in low- and middle-income countries.7 
The differences in developed- and developing-country survival 
rates are particularly high for cancers that have good prognoses with 
early diagnosis, as well as coronary heart disease and diabetes, for 
which high-income-country patients have access to relatively cheap 
and effective treatments.8 Angiotensin-converting-enzyme (ACE) 
inhibitors, beta-blockers, and insulin are long off-patent, but still 
unavailable or inaccessible in low- and middle-income countries due 
to high costs and limited supply.9 Overall, the WHO estimates that 
developing countries account for 90 percent of the nine million pre-
mature deaths from NCDs.10 
The frequent onset of NCDs among young people and the bad 
health outcomes that result are having devastating economic and 
social consequences in low- and middle-income countries. The 
chronic nature of most of these diseases means patients are sick and 
TABLE 1:  PERCEN TAGE CHANGE I N DALyS:  1990–2010
Data Source: Institute for Health Metrics and Evaluation, Global Burden of Disease Study 2010.
 Low income Lower-middle income Upper-middle income High income
All communicable diseases −14% −27% −47% −23%
All NCDs 42% 38% 18% 9%
Ischemic heart disease 71% 61% 42% −21%
Cerebrovascular disease 45% 43% 16% −17%
Lung cancer 78% 56% 52% 7%
Breast cancer 124% 58% 55% 1%
Cervical cancer 28% 19% 18% −16%
Leukemia 54% 30% −7% 1%
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suffer longer and also seek and require more medical care and hospi-
talization. The effects are felt at the household, national, and global 
levels (Exhibit 1). 
On a household level, NCDs consume budgets through out-of-
pocket health-care costs as well as absenteeism and foregone income 
for patients and caregivers.11 In Sudan, households with diabetic chil-
dren devote 65 percent of household expenditures to their care.12 In 
rural Ghana, minimum-wage earners with diabetes spend 60 percent 
of their incomes on insulin.13 To cover these costs, households take 
unsecured loans, deplete savings, or sell assets, all of which put families 
on precarious financial footing. The rates of catastrophic health expen-
ditures in India for households with a male family member suffering 
from cancer or cardiovascular disease are 44 percent and 24 percent, 
respectively.14 Premature death and disability from NCDs robs fami-
lies of their primary wage earners. 
Many diseases experienced by mothers can spread to children; 
NCDs, despite their designation as noncommunicable, are proving 
FIGURE 6:  AGE -STANDARDI zED NCD DE AT H RATE S I N ADULTS
Data Source: Institute for Health Metrics and Evaluation, Global Burden of Disease Study 2013.
E
x
H
IB
IT
 1
: 
E
F
F
E
C
T
S
 O
F
 N
C
D
S
 I
N
 L
O
W
- 
A
N
D
 M
ID
D
L
E
-I
N
C
O
M
E
 C
O
U
N
T
R
IE
S

    
 P
re
m
at
ur
e 
de
at
h 
an
d 
di
sa
bi
lit
y

    
 L
os
t h
ou
se
ho
ld
 in
co
m
e,
 p
ot
en
ti
al
 
im
po
ve
ri
sh
m
en
t

    
 H
ea
lt
h 
ex
pe
nd
it
ur
es
, i
nc
lu
di
ng
 
ca
ta
st
ro
ph
ic

    
 L
os
s 
of
 s
av
in
gs
 a
nd
 a
ss
et
s

    
 G
re
at
er
 li
ke
lih
oo
d 
of
 c
hi
ld
re
n 
de
ve
lo
pi
ng
 N
C
D
s

    
 P
oo
r 
he
al
th
 o
ut
co
m
es

    
 D
im
in
is
he
d 
ca
pa
ci
ty
 to
 a
dd
re
ss
 o
th
er
 h
ea
lt
h 
ne
ed
s

    
 R
es
ou
rc
es
 to
 r
et
oo
l h
ea
lt
h 
sy
st
em
s
to
 c
hr
on
ic
, p
re
ve
nt
at
iv
e 
ca
re

    
 H
ea
lt
h 
la
bo
r 
fo
rc
e 
an
d 
tr
ai
ni
ng
 
de
m
an
ds

    
 In
cr
ea
se
d 
de
m
an
d 
fo
r 
hi
gh
-c
os
t 
m
ed
ic
al
 in
te
rv
en
ti
on
s
Po
or
er
 G
lo
ba
l H
ea
lt
h
R
ed
uc
ed
 In
te
rn
at
io
na
l
T
ra
de
 a
nd
 D
ev
el
op
m
en
t
Po
te
nt
ia
l f
or
Po
lit
ic
al
 In
st
ab
ili
ty

    
 R
ed
uc
ed
 la
bo
r 
su
pp
ly

    
 L
ow
er
 p
ro
du
ct
iv
it
y 
an
d 
co
m
pe
ti
ti
ve
ne
ss

    
 L
ow
er
 ta
x 
re
ve
nu
es

    
 In
cr
ea
se
d 
he
al
th
 a
nd
 s
oc
ia
l w
el
fa
re
 
ex
pe
nd
it
ur
es

    
 L
os
t d
em
og
ra
ph
ic
 d
iv
id
en
d

    
 E
ro
de
d 
in
st
it
ut
io
na
l c
ap
ac
it
y

    
 P
ol
it
ic
al
 p
re
ss
ur
e 
fr
om
 u
nm
et
 
po
pu
la
ti
on
 n
ee
ds
g
lo
ba
l 
an
d
 r
eg
io
n
al
 e
ff
ec
ts
In
di
vi
du
al
s 
an
d 
H
ou
se
ho
ld
s
H
ea
lt
h 
Sy
st
em
s
N
at
io
na
l E
co
no
m
ie
s
an
d 
G
ov
er
nm
en
ts
15The Rising Epidemic of NCDs in Low- and Middle-Income Countries
no different.15 Diabetes and hypertension can impair fetal growth and 
development, and increasing evidence shows a mother’s physiological 
condition during pregnancy predisposes her newborns to adult dis-
eases such as coronary heart disease and stroke.16
On a national level, early onset of chronic illnesses consumes scarce 
health-care resources and undermines the capacity of developing-coun-
try health systems to respond to infectious and nutritional diseases and 
other health threats.17 This is particularly true in the poorest countries 
in sub-Saharan Africa and South Asia, where malnutrition, HIV/AIDS, 
and other communicable diseases remain significant problems.18 
The rise of NCDs, if unaddressed, can breed political instability and 
dissatisfaction with governments. The national health systems in most 
low- and middle-income countries are not equipped to meet the demand 
for primary and chronic care of NCDs. This retooling will require dis-
ease surveillance and registries; community-based health promotion and 
prevention programs; better health-care financing; more nurses, primary 
care physicians, and specialists; diagnostic laboratories; and cost-effec-
tive medical technologies and health-care delivery models. As the NCD 
epidemic accelerates and the health and economic outcomes worsen, 
popular demands for this health system retooling will increase, particu-
larly among the middle class. In 2013, mass protests rocked Brazil; dem-
onstrators railed against an underfunded, overcrowded health system 
and its chronic shortages of beds, medicines, and doctors.19 
Government health and welfare expenditures are not the only NCD-
related economic costs for countries. Premature death and disability 
from NCDs saps low- and middle-income countries’ labor supply and 
diminishes workforce productivity.20 This makes it harder to capitalize 
on the demographic dividend that would otherwise occur from reduced 
child mortality, better family planning, and having a larger proportion 
of young, working-age people relative to developed countries (Figure 
7). As a result, the wealth generation and productive investments that 
would arise from that dividend are reduced or lost. Consumer spending 
and savings, especially among the rising middle class, suffers. Increased 
health expenditures and lower productivity diminish national competi-
tiveness and foreign direct investment.21 Tax revenues decline.
Given the scale of the emerging NCD epidemic in low- and mid-
dle-income countries, the effects of these diseases on individuals and 
households, health systems, and national economies and governments 
reverberate globally. The World Economic Forum projects that the 
16 The Emerging Global Health Crisis
FIGURE 7:  P OPULAT ION DISTR I BU T IONS FOR LOW- AND 
M I DDLE -I NCOME COUN TR I E S By REGION
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Data Source: World Bank, World Development Indicators.
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NCD epidemic will inflict $21.3 trillion in economic losses in low- and 
middle-income countries over the next two decades, which is nearly 
the same as the total gross domestic product (GDP) of these countries 
($24.5 trillion) in 2013.22 
19
The reasons for the rising NCD epidemic in low- and middle-income 
countries begin, paradoxically, with increased life expectancy. Better 
dissemination of breastfeeding and hand-washing information and 
other low-cost improvements in birth and antenatal care have saved 
millions of newborn lives. International agencies and donor-funded 
institutions, such as UNICEF and the Global Alliance for Vaccines 
and Immunization (GAVI), have extended immunizations for mea-
sles, polio, and childhood diseases to the world’s poorest. Oral rehy-
dration salts have prevented many of the deaths in children that once 
occurred in developing countries from cholera and diarrheal dis-
ease.23 Spurred by gains in child health, life expectancies increased, 
on average, by six months per year in low-income countries between 
2000 and 2012.24 In lower-middle-income countries, the improvement 
in longevity has been slower, but still impressive: three months annually 
over the same time. 
Longer lives and increased survival beyond adolescence explain why 
more people in low- and middle-income countries get NCDs. This does 
not, however, explain why so many people in these countries are devel-
oping NCDs so much younger and with such worse outcomes than in 
wealthier nations. 
Part of the answer is that life expectancies have increased in low- 
and middle-income countries without the improvements in health sys-
tems that accompanied the rise in longevity in wealthier countries.25 
The health-care systems in most developing countries are still struc-
tured for acute care of infectious diseases and maternal and neonatal 
mortality, not preventive or chronic care.26 In many of these countries, 
medicines are still purchased out of pocket and are often beyond the 
means of poor households.27 
Health spending by low- and middle-income country governments 
has tripled over the past twenty years but remains low relative to 
The Factors Behind  
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higher-income countries (Figure 8).28 For instance, all the governments 
in sub-Saharan Africa together spend roughly as much on health annu-
ally ($33 billion) as the government of Poland ($31 billion).29 Health 
spending by all low- and middle-income country governments, repre-
senting 5.7 billion people, is less than is spent by the governments of 
Canada, France, Germany, and the United Kingdom, which have a 
combined population of 245 million.30
The benefits of urbanization, trade, and global integration of 
consumer markets to developing countries have been tremendous: 
increased food production and distribution, improved hygiene and 
sanitation, disseminated medical innovations, lengthened lives, and 
millions lifted from abject poverty. Yet these trends have also helped 
fuel a rise of NCDs and associated risk factors that is faster than low- 
and middle-income countries have been able to establish the health and 
regulatory systems necessary to adjust.
Changes in the production, marketing, and distribution of con-
sumer products globally have significantly increased developing coun-
tries’ exposure to tobacco products, alcohol, and processed food and 
FIGURE 8:  LOW- AND M I DDLE -I NCOME COUN TRy GOVERNMEN T 
HE ALT H SPENDI NG By REGION
Source: Institute for Health Metrics and Evaluation, Global Health Spending Database (2013). 
21The Factors Behind the Rising NCD Epidemic
beverages. Super- and mega-markets have penetrated every region of 
the world, even rural areas.31 Dietary diversity and consumption of 
fruits and vegetables has declined, especially in East and Southeast Asia 
and sub-Saharan Africa.32 Between 1970 and 2000, cigarette consump-
tion tripled in developing countries.33
Many developing countries lack the basic consumer protections and 
public health regulations that have been in place in most high-income 
countries for decades.34 The speed and scale of the integration of global 
consumer markets is overwhelming the little public health infrastruc-
ture that does exist in these countries. Developing countries that repre-
sent relatively small commercial markets have limited ability to demand 
labeling and content changes to food, alcohol, and tobacco products 
produced for global consumption. Multinational corporations may be 
better resourced than the governments seeking to oversee them.
Tobacco companies, in particular, have used billboards, cartoons, 
music sponsorships, and other marketing methods long prohibited in 
developed countries to spur cigarette consumption among women and 
youths.35 When countries such as Uruguay, Togo, and Namibia have 
proposed nondiscriminatory restrictions on cigarette advertising and 
labeling, multinational tobacco companies have used dispute resolution 
under trade and investment agreements to block or delay implementa-
tion.36 These tactics have helped raise tobacco sales across Asia, eastern 
Europe, and Latin America, and many expect them to do so in Africa. 
At the same time, low- and middle-income countries are urbaniz-
ing at an unprecedented rate. It took fifty years for the world’s urban 
population to increase from 220 million to 732 million in 1950. By 2008, 
more than half of the global population lived in cities, and the world’s 
urban population is expected to reach almost five billion (60 percent of 
all people) by 2030.37 The vast majority of this urbanization is occur-
ring in developing countries and in cities with fewer than one million 
residents.38 China and India have the largest urban populations; cities 
in Africa are growing the fastest.39 
The urbanization of small- and medium-size cities in developing 
countries is occurring without the improvements in economic growth 
or public health infrastructure that accompanied urbanization in 
wealthier settings.40 The result has been slums—90 percent of which 
are in developing countries—that house nearly one billion people.41 
The inhabitants of these densely packed areas, who face pollution out-
doors and the burning of fuels indoors, are more susceptible to chronic 
respiratory diseases. Slum dwellers buy more tobacco products and 
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cheap processed foods and are less likely to have access to adequate 
nutrition or public-health education.
As a result of these trends, the dominant health risks in low- and mid-
dle-income countries have changed (Table 2).42 Nearly a quarter of the 
under-age-sixty deaths in developing countries in 2010 are attributed to 
high blood pressure, smoking, and dietary risks (primarily inadequate 
intake of fruits, vegetables, and nuts).
 1990 2010
1. Childhood underweight Dietary
2. Household air pollution High blood pressure
3. Suboptimal breast feeding Smoking
4. Dietary Household air pollution
5. Smoking Childhood underweight
TABLE 2:  LE ADI NG HE ALT H R ISK S I N LOW- AND M I DDLE -
I NCOME COUN TR I E S
Data Source: Institute for Health Metrics and Evaluation, Global Burden of Disease Study 2010.
With little access to preventive care and increased exposure to behav-
ioral risks, working-age people in low- and middle-income countries are 
more likely to develop an NCD. Without access to chronic care and lim-
ited resources, these people are more likely to become disabled and die 
young as a result of their disease. 
In low-income countries, NCDs disproportionately affect the 
emerging middle class. This population has increased exposure to 
the health risks associated with NCDs but insufficient resources for 
the out-of-pocket health services to prevent or treat these diseases. 
In many lower-middle-income countries, premature NCD death and 
disability is increasingly associated with poverty, just as it is in high-
income countries.43 
With the trends underlying the emerging NCD crisis in low- and 
middle-income countries expected to persist or accelerate, the impact 
of these diseases on working-age populations in these countries will 
increase. While the share of NCD-related deaths in adults under sixty 
will continue to fall in higher-income countries, many developing coun-
tries are expected to see substantial increases (Figure 9). 
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The increase will be fastest in sub-Saharan Africa, South Asia, 
and North Africa and the Middle East, where the rates of working-
age NCD-related deaths will grow by 28 percent, 15 percent, and 12 
percent by 2025, respectively.44 Premature death from NCDs such as 
breast cancer, cardiovascular disease, and lung cancer will increasingly 
happen in poor countries alone.45 Overall, under-age-sixty deaths from 
NCDs in low- and lower- middle-income countries are projected to rise 
by more than 18 percent, to six million by 2025.46
FIGURE 9:  PREMATURE (UNDER AGE SI x T y) DE AT HS FROM NCDS
Underlying Data Source: Institute for Health Metrics and Evaluation, Global Burden of Disease Study 2013.
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The last time that the world confronted a global health challenge that 
caused such a large number of premature adult deaths and so dispro-
portionately affected low- and middle-income countries was HIV/
AIDS. The United States led the global response to that disease, and 
the world rallied to its side. The U.S. government worked with inter-
governmental institutions, donor countries, and philanthropic partners 
to establish the Global Fund to Fight AIDS, Tuberculosis (TB), and 
Malaria in 2002 and launched the President’s Emergency Plan for AIDS 
Relief (PEPFAR) in 2003. Together, these programs have delivered life-
saving antiretroviral treatments (ARVs) to millions and saved many 
lives. Competition and voluntary price cuts reduced the per-person cost 
of these medicines in poor countries from twelve thousand dollars per 
year in 1999 to two hundred dollars per year in 2003.47 Funding surged 
for research and development (R&D) of vaccines, prevention tools, and 
new and more effective combinations of ARVs. 
Since President George W. Bush launched the PEPFAR program in 
2003, the United States has committed significant resources to improv-
ing health in low- and middle-income countries. Despite the 2008 finan-
cial crisis and heated political debates over U.S. government spending, 
support for global health has remained strong, bipartisan, and one 
of the hallmarks of U.S. leadership internationally (Figure 10). U.S. 
engagement in global health has continued to increase under President 
Barack Obama and with the 2009 launch of the Global Health Initiative 
(GHI). In 2013, the U.S. Congress reauthorized and appropriated $6.7 
billion for PEPFAR and the Global Fund, the highest level of funding in 
three years.48
The U.S. government has invested in nearly eighty countries to pro-
vide proven interventions on wide-ranging global health challenges 
from malaria and tuberculosis to family planning and maternal and 
child health. Through these programs, the United States has saved 
Current Investments in Addressing  
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millions of lives and inspired the contributions of other governments 
and philanthropic donors around the world. It is an accomplishment 
that represents the very best that the United States has to offer and one 
of which every American may feel deeply proud.
U.S .  Re Sp onSe to nCDS
The U.S. response to NCDs, to date, has been modest. It currently 
has no dedicated programs or budget to address these diseases in low- 
and middle-income countries.50 Most U.S. contributions have been 
spillover benefits of international programs not specifically directed 
at NCDs, such as investment in primary health care in Haiti, research 
collaborations and public-private partnerships, and small-scale, ad hoc 
initiatives to integrate NCD-related objectives into larger existing U.S. 
global health initiatives. 
The following list contains examples of recent and current U.S. 
interventions on NCDs internationally. This list is meant to be illustra-
tive and may not be exhaustive. 
■■ The U.S. Centers for Disease Control and Prevention (CDC) par-
ticipates in the Global Tobacco Surveillance System (GTSS) and 
has advised developing-country governments on cervical cancer 
FIGURE 10:  U.S .  GLOBAL HE ALT H PROGRAMS BUDGE T,  
F y 2001–F y 2014
Source: Adapted from Wexler and Kates (March 2014).49
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screening, surveillance, and prevention programs.51 The CDC is col-
laborating with the Pan American Health Organization (PAHO) on 
the Global Standardized Hypertension Treatment Project, which aims 
to standardize the pharmacological treatment of hypertension in order 
to ease its international adoption and improve control rates.52
■■ The U.S. Department of State and the CDC Foundation sup-
port the Pink Ribbon Red Ribbon initiative, which leverages the 
PEPFAR program to promote breast cancer education and expand 
cervical cancer screening and treatment.53 Private donors and phil-
anthropic entities such as the George W. Bush Institute, Susan G. 
Komen Foundation, and the Bill & Melinda Gates Foundation pro-
vide most of the programmatic and administrative funding for this 
program. PEPFAR also provides support and technical expertise and 
helps manage the program.54 
■■ The U.S. Department of State, the Environmental Protection Agency, 
and ten other U.S. agencies support the Global Alliance for Clean 
Cookstoves, a public-private partnership that works to reduce indoor 
air pollution.55 U.S. agencies have provided $67 million in funding to 
twenty-five projects, roughly five of which are health related.56
■■ The National Institutes of Health (NIH) funds research on cancer, 
diabetes, and NCDs generally. These research programs do not target 
these particular needs of developing countries as a general matter, 
but may have spillover benefits for global prevention and treatment 
of these diseases. 
■■ NIH’s National Heart, Lung, and Blood Institute (NHLBI) and Unit-
edHealth Group began the Global Alliance for Chronic Diseases, an 
international public-private partnership that facilitates and supports 
NCD-related research collaborations via a network of eleven centers 
in thirty countries.57 
■■ NIH’s National Cancer Institute (NCI) has provided trainings on 
establishing cancer registries in low- and middle-income countries 
and contributed limited support to several sub-Saharan African 
countries to do so. NCI promotes U.S. research collaborations with 
China and five Latin American countries, participates in the Middle 
East Cancer Consortium, provides a four-week training course in 
cancer prevention, and offers a small number of grants ($75,000 to 
$350,000 each) to South African and Indian researchers working on 
low-cost cancer-related technology.58 
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■■ Between 2002 and 2012, NIH’s Fogarty International Center gave 
$37 million in grants for tobacco control research and capacity 
building in low- and middle-income countries. In 2012, the Fogarty 
Center provided $14 million in grants to fifteen international insti-
tutions to fund training in NCD-related research.59 It also supports 
bilateral scientist exchanges, workshops, and training under the NIH 
Visiting Program, some of which may be related to developing coun-
tries and NCDs.
■■ The U.S. Agency for International Development (USAID) has pro-
vided support for the Global Alliance for Clean Cookstoves, the 
Uganda Cancer Institute, and a small number of country programs, 
primarily in eastern Europe and Central Asia, that incorporate 
NCD-related objectives.60 
■■ The Millennium Challenge Corporation has integrated NCD-
related goals into at least one of its compact countries.61 
Assessing the resources dedicated to these NCD-related efforts is 
difficult because they are generally objectives added to existing U.S. 
global health programs and not budgeted for separately. The Institute 
for Health Metrics and Evaluation (IHME) tracks development assis-
tance for global health, and according to its data, the U.S. government 
dedicated $10.8 million of its more than $8 billion global health aid 
budget to NCDs in 2010.62 These aid figures do not include R&D for 
either communicable or noncommunicable diseases. 
I n teRnat Ional engagemen t on nCDS
In the absence of U.S. leadership, the international response to NCDs 
has struggled. The WHO began issuing reports in the mid-1990s that 
NCDs would soon dwarf the burden of infectious diseases and mater-
nal, perinatal, and nutritional conditions in developing countries and 
that the speed and scale of that transition would pose serious challenges 
to health-care systems and economies.63 After WHO-issued global 
strategies and action plans failed to gain traction, a group of concerned 
low- and middle-income countries and NGOs pressed the United 
Nations (UN) General Assembly to hold a high-level meeting on NCDs, 
which occurred in 2011. It is the only health issue other than HIV/AIDS 
on which the UN General Assembly has held such a meeting. 
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The 2011 UN meeting helped broaden public recognition of the 
human and economic toll of NCDs and inspired several important 
country-led initiatives.64 In May 2012, the WHO set a voluntary global 
target for reducing premature NCD mortality by 25 percent by 2025, 
reached agreement with its member states on an international moni-
toring framework, and released another global action plan on NCDs. 
More than seventy countries have sought WHO assistance to expand 
their health-care coverage and cope with the rise of NCDs.65 To sup-
port these efforts, the WHO increased its budget on NCDs by nearly 
20 percent, to $318 million.66 The NCD Alliance, launched in 2009, 
has helped mobilize more than two thousand organizations to elevate 
NCDs on the global health agenda. Yet donor aid (Figure 11), in-country 
resources, and a practical, well-prioritized agenda for collective action 
on NCDs remain elusive.67
30
This Task Force recommends that the U.S. government designate the 
prevention, diagnosis, and treatment of NCDs in low- and middle-
income countries as a priority in its global health and development 
programs. This is not a recommendation that the Task Force has come 
to lightly. The resources that the United States has to devote to global 
health are limited, and its existing commitments are many. The U.S. 
government is already the largest funder of global health and under-
standably wary to expand into new areas. With widespread concerns 
over the U.S. budget and fiscal situation, these are not auspicious times 
for new initiatives. The Obama administration has indicated an inten-
tion to sustain, but not increase, U.S. global health aid.69 
This recommendation is the unavoidable conclusion of a sober and 
data-driven assessment of U.S. interests in addressing the rising NCD 
epidemic in developing countries and the availability of proven, scal-
able interventions. Through these interventions, the United States 
may accomplish much while spending relatively little. In this chapter of 
the report, the Task Force outlines its assessment of U.S. interests in 
increased engagement on NCDs in low- and middle-income countries 
and the reasons for doing so now. The following chapter will identify 
and recommend low-cost strategies for increased U.S. engagement. 
U.S .  global He alt H I n teRe StS I n nCDS
The United States has two compelling global health interests in increas-
ing its engagement on NCDs. First, NCDs undermine the effectiveness 
of existing U.S. global health investments. Second, NCDs represent an 
opportunity for the U.S. government to build on existing U.S. global 
health platforms to achieve sustainable reductions in premature death 
and disability that disproportionately affect the poor. 
The Case for Increased U.S. Engagement
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Ensuring thE EffEctivEnEss  
of u.s. global hEalth invEstmEnts
Surveys have consistently shown that Americans’ support for global 
health depends not on the disease the United States seeks to address, 
but on the people helped and the effectiveness of aid given.70 Over the 
past decade, the U.S. government has invested in addressing HIV/
AIDS, TB, and other health challenges facing the poor in dozens of 
countries and saved millions of lives doing so. Yet the health needs of 
these countries are changing. The success of U.S. global health efforts 
cannot continue without changing also.
This Task Force finds that NCDs undermine the effectiveness of 
U.S. global health investments by causing premature death and disabil-
ity in the very same populations that the United States is spending sub-
stantial resources to save from other diseases. The lion’s share of U.S. 
global health funding is devoted to addressing HIV/AIDS. In 2013, the 
United States spent $4.7 billion on HIV/AIDS, primarily for treatment 
and prevention in low- and middle-income countries. A significant por-
tion of the $1.7 billion that the United States contributes to the Global 
Fund goes to HIV/AIDS and, to a lesser extent, malaria and TB. 
Adults between the ages of fifteen and sixty in low- and middle-
income countries represent the vast majority of those living with HIV/
AIDS and TB and those most likely to contract these diseases in the 
future. The median ages of death from HIV/AIDS and TB globally 
are 38.6 and 52.9, respectively.71 These are the same populations now 
experiencing worse health and economic effects from the rising NCD 
epidemic. Recent research indicates that PEPFAR patients in Africa 
are suffering increasing rates of NCDs such as chronic respiratory ill-
nesses, renal disease, and cervical cancer.72 It is poor stewardship of 
scarce U.S. global health resources to spend substantial resources to 
save an individual from one preventable and treatable disease while that 
individual succumbs prematurely to another preventable and treatable 
disease. This is especially true when there are low-cost, proven inter-
ventions—such as controlling hypertension or reducing tobacco use—
that would make a difference. 
The rising epidemic of NCDs undermines U.S. government invest-
ments in other areas of global health as well (Figure 12). Smoking 
increases the risks of TB infection, drug resistance, and poor treatment 
outcomes.73 Diabetes triples the likelihood of developing TB.74 High 
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blood pressure and gestational diabetes increase adverse pregnancy 
and maternal health outcomes.75 People infected with the hepatitis C 
virus, which causes liver cancer and cirrhosis, are also more likely to 
develop schistosomiasis than those who are not.76 More broadly, fail-
ure to address the rising epidemic of NCDs undermines the U.S. objec-
tive of building sustainable health systems in low- and middle-income 
countries and their ability to assume ownership of U.S. programs on 
communicable disease and maternal health.
To assess the potential threat of NCDs to the progress achieved 
thus far by U.S. global health investments, the Task Force undertook 
a detailed analysis of the low- and middle-income countries where the 
U.S. government currently has significant health investments. The anal-
ysis assessed the leading health risk factors and the premature (under 
age sixty) burden of NCDs relative to HIV/AIDS, TB, malaria, and 
FIGURE 12:  U.S .  F y13 GLOBAL HE ALT H FUNDI NG
Data Source: Henry J. Kaiser Family Foundation, 2014.77
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maternal, newborn, and child health (MNCH). The countries assessed 
include twenty-nine designated as priorities under the GHI78 as well as 
twenty other countries that received more than $5 million in U.S. health 
aid in 2013.79 The annex to this report includes case studies on each of 
these forty-nine countries (hereafter “U.S. priority countries”).80 
NCDs are rising in young, working-age populations in these U.S. pri-
ority countries and resulting in poor health outcomes. NCDs accounted 
for 28 percent of the premature deaths and a third of the DALYs in the 
priority countries in 2010 (Figure 13). These rates are 3.5 times greater 
than premature deaths and 5.5 times greater than disability attributed 
to HIV/AIDS in these countries. In the same year, NCDs were respon-
sible for 1.6 times as many premature deaths as malaria, TB, and HIV 
combined in these priority countries. Four of the five leading health 
risks in these countries are behavioral and clinical risks for NCDs—
diet, indoor air pollution, tobacco smoking, and high blood pressure. 
The health outcomes for those who develop NCDs in these forty-nine 
U.S. priority countries are poor (Figure 14). In recent years, women and 
FIGURE 13:  CAUSE OF HE ALT H BURDEN I N U.S .  PR IOR I T y 
COUN TR I E S
Data Source: Institute for Health Metrics and Evaluation, Global Burden of Disease Study 2010.
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children have been a particular focus of these U.S. global health invest-
ments. The health outcomes are particularly bad for women and girls 
who have one or more NCD in these priority countries; in 2010, they 
had an 83 percent higher age-standard death rate than in high-income 
countries.81 These outcomes reflect the disproportionate challenge 
that NCDs represent to women and children in developing countries. 
Women in these settings often lack control over household resources 
and hence have less access to diagnosis, prevention, and care for NCDs 
for themselves and their children. Ninety-two percent of the cases of 
hyperglycemia (high blood glucose) in pregnancy occur in developing 
countries, mostly to women unaware of their condition or its elevated 
risks for obstructed labor and preeclampsia.82 Acute rheumatic fever is 
a leading cause of cardiovascular disease in sub-Saharan Africa, mostly 
affects youth, and is generally caused by delayed or inadequate treat-
ment of strep infections in children.83
On a national level, NCDs will deplete scarce health-care resources in 
these priority countries, making it harder for those governments strug-
gling to address still-high rates of childhood malnutrition and infectious 
FIGURE 14:  AGE -ADJUSTED NCD RATE S FOR U.S .  PR IOR I T y 
COUN TR I E S
Data Source: Institute for Health Metrics and Evaluation, Global Burden of Disease Study 2010.
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diseases such as TB and HIV/AIDS. In doing so, preventable and pre-
mature deaths and disability from NCDs diminish the value of the U.S. 
investments in building sustainable health systems in poor countries.
lEvEraging Existing u.s. global hEalth 
invEstmEnts to rEducE thE burdEn of 
PrEvEntablE and PrEmaturE dEaths duE to ncds
NCDs are similar to many existing U.S. global health priorities. As with 
prenatal and maternal care, family planning, nutrition, and reproduc-
tive health care, the health of U.S. citizens does not directly depend on 
reducing NCDs abroad. And as with HIV/AIDS, which is transmit-
ted primarily through unprotected sex and intravenous drug use, most 
of the risk factors for NCDs are behavioral, such as tobacco use and 
indoor pollution. Roughly half of the countries that received $5 million 
or more in U.S. health assistance in 2013 were lower-middle- or middle-
income countries, and it is in these same countries that the burden of 
NCDs is the greatest.84 But the most important way in which NCDs are 
similar to other U.S. global health priorities is that these diseases cause 
significant amounts of preventable and premature death and disability 
among the poor that U.S. leadership could help sustainably reduce.
U.S. leadership in global health is a rare area of political consensus in 
increasingly partisan times. The durability of that leadership in global 
health reflects American values—compassion, charity, and a willing-
ness to share U.S. technological advances in disease prevention, diag-
nosis, and treatment with the poor who need them.85 By doing so, the 
United States affords millions of underserved and vulnerable people the 
opportunity to lead healthy and productive lives. In deciding to approve 
the proposal for the PEPFAR program, President George W. Bush 
reportedly asked how the United States would be judged if it did not act 
to address a preventable and treatable epidemic of such magnitude.86 
The analysis of the forty-nine U.S. priority countries where the 
United States has significant global health investments demonstrates 
that NCDs are the dominant, fast-emerging challenge facing the poor, 
underserved, and vulnerable in these settings. Established U.S. pro-
grams in these countries to address HIV/AIDS, TB, and maternal and 
child health offer an existing platform for NCD prevention, screening, 
and treatment. Relatively inexpensive opportunities abound. 
A decade into PEPFAR, the U.S. government has developed exten-
sive experience supporting quality care for chronic conditions in 
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resource-poor settings. PEPFAR is the largest chronic-care program 
in many low- and middle-income countries. NCD prevention and 
treatment strategies incorporate similar elements of management of 
HIV/AIDS: promotion of healthy behaviors, long-term adherence to 
prescribed treatment, consistent monitoring of treatment outcomes, 
and patient engagement in care and treatment decisions.87 The same 
approaches that the U.S. government uses to ensure safe, reliable sup-
plies of AIDS and malaria treatment, childhood vaccines, and con-
traceptives could be leveraged to improve access to the essential and 
generally off-patent medicines needed to address NCDs in developing 
countries. U.S. nutrition programs targeting the first one thousand 
days of life can simultaneously help address NCDs. Increasing evidence 
shows low-birth-weight babies who gain weight rapidly in childhood 
suffer greater risks of hypertension and diabetes later in life.88 
There are existing examples of successful NCD programs that lever-
age HIV/AIDS program platforms. Integration of HIV/AIDS, diabetes, 
and hypertension management in Cambodia has demonstrated high 
acceptance and good outcomes.89 A successful low-technology screen-
and-treat program for cervical cancer in women with HIV was piloted 
through PEPFAR in Zambia.90 A clinic in Uganda uses the same staff 
and systems to offer services for HIV on some days and for diabetes and 
heart disease during the remainder of the week.91 PEPFAR has inte-
grated other global health objectives such as family and reproductive 
care, maternal health, and nutrition into its programs and platforms.92 
More research is needed to ensure integration of NCD objectives is 
cost-effective, does not diminish the effectiveness of HIV-related pro-
gramming, and reaches the target patient population—men—as well as 
women and children. 
U.S .  eConom IC anD StRategIC I n teRe StS 
I n aDDRe SSI ng nCDS
Speaking before the United Nations, President Obama cited global 
health as not only a moral objective but also a U.S. strategic and economic 
imperative.93 The 2000 U.S. National Intelligence Estimate, titled The 
Global Infectious Disease Threat and Its Implications for the United States, 
likewise recognized the importance of global health to the achieve-
ment of these foreign policy and trade objectives.94 These conclusions 
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have been reaffirmed and reinforced in the 2010 U.S. National Security 
Strategy, the U.S. State Department’s 2012 Quadrennial Diplomacy 
and Development Review, and National Intelligence Council reports.95
The Task Force finds that the United States has two compelling 
strategic interests in increasing its engagement on NCDs. First, the 
United States has an important interest in fostering the long-term 
capacity of low- and middle-income countries to prevent and reduce 
premature NCD-related death and disability as a means of support-
ing economic development and promoting U.S. exports. Second, the 
United States has interests in enhancing the credibility of U.S. global 
health programs and building fruitful partnerships with capable allies 
and rising powers.
u.s. Economic intErEsts in addrEssing ncds
U.S. global health investments help expand the ranks of prosperous 
and capable states, particularly in Africa; build a more stable, inclusive 
global economy; and unleash the potential of previously impoverished 
and vulnerable populations. In doing so, the United States advances its 
own interests in international trade, U.S. exports, and American jobs. 
Ninety-five percent of the world’s customers and 75 percent of global 
purchasing power now reside beyond U.S. borders. Developing coun-
tries have represented roughly half of global growth since the 2008 
financial crisis.96 U.S. private-sector investments in sub-Saharan Africa 
over the past decade have yielded among the highest rates of return of 
any region in the world.97 In 2013, the United States exported $706 bil-
lion in goods and services to low- and middle-income countries.98 As 
developing countries become wealthier, their demand for exports is 
expected to grow and shift to the categories in which the United States 
leads the world: civilian aircraft, pharmaceuticals, machinery and 
equipment, high-value foods, and entertainment.99 
NCDs undermine the continued prosperity of low- and middle-
income countries. Few other threats can compare with the human and 
economic toll that NCDs are projected to exact in these countries. The 
frequent onset of NCDs among young people and the bad health out-
comes that result have devastating economic and social consequences 
(Figure 15). The chronic nature of most of these diseases means patients 
are sick and suffer longer and they seek and require more medical care 
and hospitalization. 
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In low-income countries, the risk of premature NCD death and dis-
ability is highest among the emerging middle class. Low-income coun-
tries cannot sustain economic growth unless their middle-class and 
working-age people survive. In many lower- and middle-income coun-
tries, premature NCD death and disability is increasingly associated 
with poverty, just as it is in high-income countries.100 The World Eco-
nomic Forum has ranked NCDs as a greater threat to global economic 
development than fiscal crises, natural disasters, and transnational 
crime and corruption.101
u.s. stratEgic intErEsts in addrEssing ncds
U.S. investments in global health are visible, concrete, and highly valued; 
they save lives and have enhanced U.S. credibility around the world.102 
Although U.S. generosity on HIV/AIDS, maternal and child health, and 
other global health challenges will always be valued, it will be increas-
ingly difficult to justify—to both U.S. taxpayers and aid recipients—
such a disproportionately small share going to the diseases and risk 
factors that cause the majority of preventable death and suffering in the 
working-age poor in the countries where U.S. investments occur. 
In the forty-nine U.S. priority countries, IHME data indicates that 
the U.S. government spent in 2010 $44.17 in aid per each DALY lost to 
FIGURE 15:  PROP ORT ION OF NCD DALyS AMONG ALL DALyS  
By AGE
Data Source: Institute for Health Metrics and Evaluation, Global Burden of Disease Study 2010.
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HIV/AIDS, $4.21 for each DALY lost to malaria, and $1.41 per mater-
nal, child, and nutritional health DALY, but $0.02 for each DALY lost to 
NCDs.103 The discrepancies in U.S. global health spending will grow in 
the coming years as the NCD crisis expands in low- and middle-income 
countries—particularly in South Asia and sub-Saharan Africa—and 
continues to afflict young people disproportionately.
Global health has also long been and remains one of the important 
ways in which the United States advances its foreign policy interests in a 
just and sustainable international order that fosters peace, stability, and 
cooperation on meeting global challenges.104 The U.S. National Intelli-
gence Estimate in 2000 was the first to consider these strategic interests 
in the context of nontraditional health threats:
Chronic, noncommunicable diseases; neglected tropical diseases; 
maternal and child mortality; malnutrition; sanitation and access 
to clean water; and availability of basic health care also affect the 
U.S. national interest through their effects on the economies, gov-
ernments, and militaries of key countries and regions.105
The FY 2013 distribution of development assistance reflects U.S. stra-
tegic interests in countries, but not yet in the NCDs or other nontradi-
tional health threats that these countries face. Substantial U.S. aid went 
to address health challenges in strategically important countries such as 
Afghanistan, Jordan, Lebanon, India, Pakistan, Ukraine, Indonesia, and 
Vietnam.106 Smaller amounts of U.S. health assistance, between $1 mil-
lion and $4 million, supported health programs in Brazil, China, Egypt, 
Georgia, and Thailand in FY 2013.107 
The premature burden of NCDs in all these countries dwarfs the 
rates of HIV/AIDS, malaria, TB, and the other current targets of U.S. 
health programs. The World Bank, for example, estimates that one-
third of people in Ukraine die before the age of sixty-five, overwhelm-
ingly from NCDs.108 Another World Bank study concluded that NCDs 
reduce the labor supply in Egypt by approximately 19 percent, at a loss 
of roughly 12 percent of GDP.109 The prevalence of NCDs is staggering 
in India and China and growing rapidly in Brazil, Indonesia, and Paki-
stan (Table 3). 
NCDs and their associated health-care costs are a pressing concern 
for the economies and governments of countries of U.S. strategic inter-
est and an important, untapped opportunity for collaboration. This is 
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particularly true in the emerging nations where NCDs are starting to 
strain institutional capacity and spur political instability. Concerns over 
the health effects of environmental pollution and inadequate health-
care systems have already led to mass protests in China and Brazil.110 
As the NCD epidemic expands, the economic costs of these diseases 
on working-age people and households could escalate into popular dis-
satisfaction with the governments in other countries and regions where 
U.S. interests lie. 
 premature nCD deaths nCD DalYs
1. India (1.7 million) China (244 million)
2. China (1.6 million) India (236 million)
3. Russia (0.4 million) Russia (48 million)
4. Indonesia (0.3 million) Indonesia (45 million)
5. Pakistan (0.2 million) Brazil (38 million)
TABLE 3:  COUN TR I E S WI T H T HE LARGE ST NCD BURDEN
Data Source: Institute for Health Metrics and Evaluation, Global Burden of Disease Study 2010.
u.s. intErEsts in addrEssing ncds now
The Task Force finds that the United States has strong interests in not 
only increasing its engagement on the rising NCD epidemic in develop-
ing countries, but in doing so now. The costs of child and adult health 
are diverging in low- and lower-middle-income countries (Figure 16).111 
Even poor countries are achieving the low child mortality rates that 
were once only possible in wealthy countries. The opposite is true for 
adults; the economic growth that developing countries must sustain just 
to achieve the health performance that existed in developed countries 
more than sixty years ago has risen sharply since the mid-1990s. Those 
trends are independent of HIV/AIDS—a variable for which Figure 16 
controls—and occur despite dramatic declines in communicable dis-
eases over the same time period. NCDs are the reason.
Three conclusions emerge from this analysis. First, effectively 
addressing NCDs in low- and lower-middle-income countries is likely 
to become more difficult with each passing year of inaction. Second, 
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economic growth alone is unlikely to solve the NCD crisis in most of 
these countries. Fewer developing countries will be able to keep pace 
with the fast-growing costs of the NCD epidemic, particularly as work-
ing-age adults (ages fifteen to fifty-nine) begin to represent the majority 
of their populations. Third, effective, relatively low-cost international 
initiatives can make a difference, as they have with child health. U.S. 
programs on immunization, oral rehydration, and birth and antenatal 
care have contributed to the dramatic improvement in child and infant 
health in poor countries over the past twenty years. 
There are time-limited opportunities for the United States to work 
with partner countries and donors to help prevent critical expansions in 
the NCD epidemic. For example, tobacco-use rates in Africa are rela-
tively low but projected to increase.112 Personal income and consumer 
spending are rising, and the populations in the region are young.113 
Youths in many of these countries are beginning to smoke earlier than 
in past generations, sometimes at age eight or nine.114 Many African 
FIGURE 16:  GDP PER CAPI TA A SSOCIATED WI T H LOW- AND 
LOWER-M I DDLE -I NCOME COUN TR I E S ACH I E VI NG T HE MEDIAN 
MORTALI T y RATE S T HAT E x ISTED I N H IGH -I NCOME COUN TR I E S 
I N 1950
Data Source: Institute for Health Metrics and Evaluation, Global Burden of Disease Study 2013.
42 The Emerging Global Health Crisis
governments have not yet implemented effective tobacco control pro-
grams. The American Cancer Society projects that, unless urgent action 
is taken, Africa will have the second-most smokers of any region by 
2060.115 Many African governments lack the health-care resources and 
infrastructure to cope with the epidemic of tobacco-related diseases 
that would result.116 Timely U.S. leadership can help countries avoid 
that outcome.
The United States also has an opportunity to leverage the Septem-
ber 2015 announcement of the UN Sustainable Development Goals 
(SDGs), which will succeed the Millennium Development Goals 
(MDGs) when they expire in 2015. The SDGs are expected to include 
objectives on reducing premature NCD-related deaths by one-third 
by 2030 and strengthening implementation of the WHO Framework 
Convention on Tobacco Control.117 With U.S. leadership and sup-
port, these objectives could play a similar catalytic role as the MDGs, 
which many credit with helping inspire the rapid increase in inter-
national aid to address HIV/AIDS, malaria, and maternal and child 
health.118 The SDGs also correspond well to the strategy and recom-
mendations for U.S. engagement on NCDs that are outlined in the 
next section of this report.
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Even when limited to the four diseases causing the majority of the NCD 
burden in low- and middle-income countries, cancers, cardiovascular 
diseases, chronic respiratory illnesses, and diabetes involve a wide 
range of risk factors and potential prevention and treatment strategies. 
Stemming the rise of these diseases will require developing countries 
to retool their health-care systems to provide preventive and chronic 
care, improve urban design, and maintain effective regulatory, agricul-
tural, and public health systems. These are challenges that high-income 
countries share, including the United States. The difference is that 
demographic and economic changes are forcing developing countries 
to confront those challenges faster and with fewer resources.
Determining health priorities and allocating resources in the face 
of the emerging NCD epidemic are decisions for national govern-
ments. Yet the direction of those decisions is deeply influenced by 
the priorities of the United States, as are the priorities of the other 
donor governments, nongovernmental organizations, and philan-
thropic institutions that compose the global health community. U.S. 
support for cost-effective NCD programs would reduce preventable 
death and disability, demonstrate the feasibility of doing so, and raise 
expectations and accountability for local governments and other 
global health actors. 
The Task Force finds that increased engagement on the rising epi-
demic of NCDs is vital to U.S. interests—in improved global health, 
increased international trade and development, and U.S. standing and 
strategic objectives around the world. The Task Force also finds that, 
conversely, U.S. leadership can make an enormous difference in help-
ing developing countries meet the NCD challenge, but the role for U.S. 
intervention is necessarily limited to the areas and activities in which it 
may be effective. 
How the United States  
Can Make a Difference
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a StRategY foR U.S .  engagemen t
This Task Force has been asked to recommend practical, scalable ways 
that the U.S. government can work with like-minded partners to help 
address the rising NCD epidemic in low- and middle-income countries, 
even in these austere times. We have come together on a strategy and a 
set of concrete recommendations that we believe offers the broad out-
line of a workable way forward.
The Task Force recommends that U.S. investments in NCDs should 
focus initially on the specific NCDs and risk factors that are (a) espe-
cially prevalent among working-age populations of the developing-
country poor and for which (b) effective and low-cost interventions 
exist that are (c) amenable to collective action and (d) can leverage 
existing U.S. programs and platforms. These efforts should be coun-
try-specific and designed in cooperation with the local government to 
be responsive to its needs, interests, and capacities. U.S. interventions 
should be rigorously and transparently monitored to maintain congres-
sional and public support and, if proven cost-effective, to promote their 
broader adoption by low- and middle-income countries. Where pos-
sible, U.S. efforts should leverage regional platforms, which would pro-
mote knowledge sharing and technical capacity of other countries not 
directly targeted by U.S. NCD investments. 
We have applied these criteria to the specific diseases and health 
risks that are causing large numbers of premature deaths in low- and 
middle-income countries but far fewer in high-income countries due 
to the widespread availability of effective prevention and treatment 
measures. In large part, it is these diseases and risks that are responsible 
for the divergence in the NCD epidemics in developed and developing 
countries. Assessment of these diseases and risk factors provides the 
basis for this Task Force’s recommendations in three categories: chal-
lenges on which U.S. leadership could make a tremendous difference 
on NCDs now; challenges on which U.S. leadership could make a tre-
mendous difference in the near term; and shared challenges on which 
increased U.S. collaboration with developing-country governments 
and the private sector may yield cost-effective ideas of mutual benefit.
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The Task Force recommends actions to address four challenges on 
which U.S. engagement would make a difference now and meet the 
selection criteria outlined earlier. Each challenge is especially preva-
lent among working-age populations in the low- and middle-income 
countries where the United States has existing platforms for action. 
Low-cost, prevention-based solutions exist for each challenge, and the 
United States is in the position to help local governments implement 
them. Each challenge is one on which U.S. leadership would reduce the 
burden that the rising epidemic of NCDs is posing to governments, 
economies, and, most important, people in low- and middle-income 
countries. A brief investment case is provided for each challenge. 
CaRDIovaSCUlaR DISe aSe
Cardiovascular diseases in low- and middle-income countries cause thir-
teen million deaths each year, more than a quarter of all deaths in these 
countries. Most of these cardiovascular deaths result from ischemic heart 
disease, also known as coronary heart disease, and cerebrovascular dis-
ease, which produces strokes.119 These diseases present a substantial and 
rising threat in the same forty-nine countries where the United States has 
substantial annual health investments (Figure 17). 
availability of ProvEn intErvEntions
Given that cardiovascular diseases produce so many NCD-related 
deaths in developing countries, effective prevention and treatment 
strategies could save a large number of lives. Fortunately, these strate-
gies exist and are in widespread use in high-income countries. Despite 
NCD Challenges on Which U.S. 
Leadership Would Make a Difference Now
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increasing rates of obesity, the United States cut mortality rates from 
these diseases by more than 40 percent between 1980 and 2000.120 
Mortality from stroke and coronary heart disease has declined by as 
much as two-thirds in some high-income countries.121 
Two factors contributed to this improvement. First, there were sub-
stantial declines in smoking, hypertension, and other risk factors in 
high-income countries. Second, there has been a revolution in the effec-
tiveness of treatments. 
Hypertension, also known as high blood pressure, is responsible for 
an estimated one-half of the global deaths and disability from coronary 
heart disease and nearly two-thirds of the deaths and disability from 
stroke worldwide.122 In parts of Africa, Asia, and eastern Europe, prev-
alence of high blood pressure exceeds 45 percent.123 Hypertension con-
trol can be achieved using existing and off-patent medications such as 
diuretics, calcium channel blockers, ACE inhibitors, and beta-blockers. 
The Institute of Medicine recommends hypertension control programs 
as an ideal first step for cardiovascular disease prevention and control 
FIGURE 17:  CHANGE I N PREMATURE CARDIOVA SCULAR DE AT HS 
I N U.S .  PR IOR I T y COUN TR I E S,  1990–2013
Data Source: Institute for Health Metrics and Evaluation, Global Burden of Disease Study 2013.
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because the health benefits accrue in a relatively short time. Hyperten-
sion management is also a good platform for adding other future pre-
vention objectives on tobacco use and high blood-lipid levels, a risk 
factor for diabetes.124 
In adults who have had a previous stroke or heart attack, use of aspi-
rin, beta-blockers, and ACE inhibitors is especially effective. Taken 
independently, these drugs reduce the risk of reoccurrence of cardio-
vascular events by about one-quarter; taken in combination, these drugs 
reduce reoccurrence by two-thirds to three-quarters.125 Implementing 
secondary prevention of cardiovascular disease requires a commitment 
to community surveillance programs and the collection of mortality 
and morbidity data to identify high-risk individuals.126 Advanced pro-
filing has been used in the treatment of hypertension in South Africa 
and found to be a cost-effective means of targeting those at higher risk 
in resource-poor environments. 127
what thE unitEd statEs has to offEr
The same strategies that U.S. officials employed toward tuberculosis 
control in New York City and have supported internationally would 
make a significant contribution to reducing the large premature 
burden of cardiovascular disease in low- and middle-income coun-
tries. These strategies include standardizing and simplifying diagnos-
tic and treatment protocols; ensuring a consistent supply of essential 
quality-assured medicines; identifying at-risk individuals participat-
ing in other health-care services; and systematic monitoring and eval-
uation of outcomes and patients. This approach has been successfully 
piloted for hypertension at an HIV clinic in Malawi that treats fifty 
thousand patients and relies on nurses to provide most of the associ-
ated health services.128
To make this strategy work on a broader scale, more support should 
be devoted to scaling CDC collaboration with PAHO on the Global 
Standardized Hypertension Treatment Project. This program could 
make a critical contribution to standardizing cost-effective pharma-
cologic treatment of hypertension, easing its international adoption, 
and improving high-blood-pressure control rates globally.129 More 
resources would allow that process to occur much faster and be imple-
mented in other regions.
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ACE inhibitors, beta-blockers, and many statins are off-patent but 
still unavailable in many developing countries. The recent Prospec-
tive Urban Rural Epidemiology (PURE) study found that 69 percent 
of patients in lower-middle-income countries and 80 percent in low-
income countries did not receive these medications at all, compared to 
only 11 percent of high-income-country patients. Many of these prod-
ucts lack international suppliers or are difficult for still-nascent devel-
oping-country regulatory authorities to oversee.130 
The United States should seek to expand existing procurement 
and treatment platforms, such as PEPFAR, to include hypertension 
medicines and help ensure the quality, safety, and consistent supply of 
these cardiovascular medicines. Assisting the WHO in expanding its 
prequalification program to NCD medicines would compensate for 
developing-country regulators who are still unable to register and over-
see these products. Development of these procurement and regulatory 
pathways should engage multilateral and bilateral development agen-
cies, medical societies, public and private payers, pharmaceutical and 
medical-device companies, and health technology assessment experts 
to ensure rational use of these technologies.
Another way to address drug availability and affordability is through 
a combination of generic cardiovascular disease medications known 
as the polypill. This single intervention would improve patient adher-
ence to treatment regimes, but it requires more clinical research in low-
resource settings before it may be used in at-risk populations that have 
not yet experienced a cardiovascular attack. The United States should 
support this research and, if it proves successful, promote the rollout 
of the polypill through global health product procurement platforms.
Finally, the United States should leverage its global health programs 
to identify patients with a history of heart disease or risk of developing 
one. Once the most relevant settings are identified, the United States 
should pilot cost-effective, low-resource hypertension monitoring and 
treatment programs and build registries. Hypertension registries col-
lect and store clinical information on patients who have the condition 
and create the evidence base for evaluating the effectiveness of inter-
ventions and changes in population needs. Once established for hyper-
tension, these registries may later be expanded to monitor other health 
risks such as tobacco use and glycemic control.
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cost-EffEctivEnEss
High blood pressure is a major contributor to both coronary heart dis-
ease and stroke. Even small decreases in the incidence of high blood 
pressure could have a profound effect on lowering cardiovascular dis-
ease rates. Aspirin and beta-blocker usage studies have shown them 
to be highly cost-effective.131 The Disease Control Priority Network, 
a collaboration between the World Bank, the Bill & Melinda Gates 
Foundation, the University of Washington, and other leading health 
organizations, has determined acute management of heart attacks with 
low-cost drugs is highly cost-effective, generating twenty-five dollars in 
health and economic savings for every dollar of investment. 
PotEntial imPact
The benefits of reducing cardiovascular disease risks are not only large 
but can be realized within five years. The full benefits of most other NCD 
interventions, such as smoking cessation, take longer to manifest.132 
As a rough indication of what is possible with U.S. leadership, the 
Task Force estimated the expected increase in cardiovascular deaths in 
the forty-nine U.S. priority countries and the increase that would exist 
if those countries made improvements at the same rate that the average 
high-income country did between 2000 and 2013 (Figure 18). The dif-
ference between those projections is 3.5 million premature deaths and 
14.2 million deaths overall in eleven years in just those priority coun-
tries. The projection accounts for the expected demographic changes in 
each country, such as population growth and aging.
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tobaCCo
Tobacco use is the second leading cause of disease and premature death 
worldwide, behind hypertension. In response to stagnating sales in 
high-income nations, multinational companies have targeted low- and 
middle-income countries with still-limited tobacco tax and regulatory 
systems.133 Unless international tobacco control efforts improve, and 
soon, the WHO projects tobacco-related illnesses will kill eight mil-
lion people annually by 2030 and one billion by the end of this century, 
mostly in developing countries.134 
Figure 19 is a partial indication of the increasing threat that tobacco 
represents to the same countries wherein the United States has sub-
stantial annual health investments. Seventy percent of lung cancer 
deaths worldwide are due to tobacco use; smokers are twenty times 
more likely to perish from that disease than nonsmokers.135 The rise 
in cigarette smoking has already made lung cancer the most common 
cancer and cause of death from cancer in low- and middle-income 
countries.136
FIGURE 18:  PROJECTED PREMATURE CARDIOVA SCULAR DE AT HS 
I N U.S .  PR IOR I T y COUN TR I E S,  2014–2025
Underlying Data Source: Institute for Health Metrics and Evaluation, Global Burden of Disease Study 2013.
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FIGURE 19:  CHANGE I N PREMATURE LUNG CANCER DE AT HS I N 
U.S .  PR IOR I T y COUN TR I E S,  1990–2013
Data Source: Institute for Health Metrics and Evaluation, Global Burden of Disease Study 2013.
Lung cancer is an incomplete measure of the consequences of 
tobacco use and secondhand smoke because they are also the leading 
risk factors for other cancers and all the major NCDs—diabetes, car-
diovascular disease, and respiratory disease.137 Tobacco use increases 
health risks at every stage of life: pregnancy complications, congenital 
abnormalities, childhood illnesses, TB infection, drug resistance, poor 
treatment outcomes, and increased mortality.138 Forty percent of the 
world’s children—700 million—breathe secondhand tobacco smoke at 
home and suffer increased rates of asthma and lower-respiratory infec-
tions as a result.139 Stopping smoking can lead to a gain of about ten 
years in life expectancy.
availability of ProvEn intErvEntions
Tobacco control works. Comprehensive tobacco control programs are 
cost-effective and evidence based.140 A recent review of more than one 
hundred econometric studies concluded that tobacco taxes and con-
sumption are strongly inversely correlated, particularly in low- and 
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middle-income countries.141 According to the World Bank, each 10 per-
cent increase in the retail price of tobacco products in developing coun-
tries reduces tobacco consumption by roughly 8 percent and tobacco 
use prevalence by about 4 percent.142 Youths and low-income smokers 
are more likely to quit in response to price increases.143 Bans on direct 
and indirect advertising or promotion of tobacco products, particularly 
when comprehensive, have likewise been shown to reduce consump-
tion.144 Strong evidence also exists that bans on smoking in public 
places reduce exposure to secondhand tobacco smoke and can help 
decrease overall cigarette consumption.145 
These strategies have worked in developing and developed countries 
alike. Higher excise taxes, bans on smoking in public settings, and market-
ing restrictions combined with the increased stigmatization of tobacco 
use through public health campaigns and civil suits have more than 
halved adult smoking rates from 42 percent to 19 percent in the United 
States since 1965.146 Mexico, which has long had high cigarette taxes, is 
one of only four countries worldwide to reduce smoking by more than 50 
percent in both men and women since 1980. In 2008, Turkey raised ciga-
rette taxes to 81 percent and banned tobacco advertising and smoking in 
public places. The following year, hospital emergency room admissions 
in Turkey for smoking-related disease declined by nearly a quarter and 
smoking rates dropped 16 percent over three years.147 
Platforms already exist for establishing and expanding effective 
tobacco control programs in low- and middle-income countries. The 
WHO Framework Convention on Tobacco Control (FCTC) provides 
a blueprint for comprehensive tobacco control by prescribing specific 
domestic tobacco control strategies to reduce the supply and demand 
for tobacco products. The FCTC is binding and one of the world’s most 
widely subscribed treaties, with 176 member countries representing 
more than 90 percent of the world’s population.148 The FCTC entered 
into force in 2005 and, like nearly all treaties concluded since that time, 
the U.S. Senate has yet to approve it. The United States has signed the 
FCTC, however, and is fully compliant with its terms. 
In 2008, the WHO, with support from Bloomberg Philanthropies, 
developed MPOWER, a package of evidence-based and measurable 
strategies to support FCTC implementation at the country level.149 
In subsequent years, adoption of MPOWER measures on tobacco 
advertising and health warning labels has improved in low- and middle-
income countries, including in the forty-nine U.S. priority countries, 
but continues to lag in other areas and especially on tobacco taxes.150 
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what thE unitEd statEs has to offEr
Tobacco control requires a mix of expertise and inputs—taxation, 
product regulation, surveillance, and program monitoring and evalua-
tion—that have not historically resided at the WHO or national health 
ministries. U.S. agencies have that expertise and should work with 
international partners to provide the technical assistance that low- and 
middle-income country governments need.
CDC support for international tobacco control surveillance is 
invaluable and cheap, performed on a budget of $3 million in 2009.151 
This Task Force recommends that the CDC should be appropriated the 
resources to increase that budget and expand its international tobacco 
programs to the lowest-income countries, where tobacco use is rising 
fastest and surveillance data is least reliable.
Implementing effective tobacco taxation is complicated by fac-
tors that vary between countries and cultures. These factors include 
tobacco use prevalence, price elasticity, the availability of counterfeit 
tobacco products, and earmarking to maintain sustainability of taxation 
schemes.152 Some low-income countries lack the capacity and exper-
tise to administer and collect excise taxes. The Task Force recommends 
that U.S. agencies with the necessary expertise partner with the World 
Bank and the International Monetary Fund (IMF) to provide technical 
assistance to interested developing countries on tobacco taxation and 
suppression of the illicit cigarette trade. This recommendation would 
build on a successful pilot that Bloomberg Philanthropies and the Bill & 
Melinda Gates Foundation funded that temporarily placed two CDC 
tax specialists at the World Bank to help the Philippines, Russia, and 
other countries implement or increase tobacco taxes.153 
Product labeling and the regulation of nicotine, tar, and tobacco 
additives are important components of limiting the public health 
impact of cigarettes. Most developing countries do not have the reg-
ulatory acumen to implement these programs. In 2009, Congress 
granted the U.S. Food and Drug Administration (FDA) the man-
date for tobacco product regulation. It is now one of only a handful 
of national regulatory agencies with expertise in this area. Congress 
should expand the resources of the FDA to work with interested devel-
oping countries to implement tobacco product regulations pursuant 
to the FCTC.
The opportunities to leverage U.S. global health platforms exist. The 
Task Force supports the integration of tobacco education and cessation 
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into U.S. maternal and child health and TB initiatives. These programs 
engage populations at risk for tobacco use, particularly girls in develop-
ing countries. 
Finally, the Obama administration has announced its intention to 
safeguard tobacco control laws and regulations from unnecessary trade 
and investment challenges under the Trans-Pacific Partnership, a pend-
ing trade deal between the United States and eleven other countries. 
The Task Force believes that this announcement provides an important 
opportunity to forge an appropriate balance of U.S. trade and global 
health priorities. The Task Force urges the Obama administration to 
negotiate an exception that encompasses the full range of nondiscrimi-
natory tobacco control measures addressed under the FCTC and per-
mitted under U.S. law.154
availablE cost EstimatEs
Improved tobacco control is first among WHO “best buy” strategies for 
addressing NCDs. It is cost-effective and, due to its emphasis on taxa-
tion, revenue generating. The Disease Control Priority Network esti-
mates comprehensive tobacco control programs in developing countries 
also generate a return of forty-to-one in health-care costs saved. 
Yet tobacco control programs do require resources to establish. This 
Task Force recommends that the United States work with other donors 
to create a multi-donor trust fund at the World Bank, which would pro-
vide seed funding to interested low-income countries to institute and 
enforce tobacco tax legislation until it becomes self-sustaining. The Bill 
& Melinda Gates Foundation established a similar World Bank trust 
fund to support global medicines’ regulatory harmonization with $12.5 
million over five years, which has been successful and subsequently sup-
ported by the United Kingdom and PEPFAR.155
Doubling the current $3 million CDC budget for international 
tobacco control surveillance would be low cost but would help generate 
the timely, accurate data that governments and donors need to address 
increased tobacco use in low-income countries. The other recommenda-
tions of this Task Force on tobacco would likewise be relatively cheap—
mostly staffing, travel, and funding for pilot projects to integrate tobacco 
control into existing U.S. global health platforms and programs. 
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PotEntial imPact
The potential benefits from increased U.S. leadership on interna-
tional tobacco control are substantial. Deaths from tobacco generally 
occur years after its use. Nevertheless, as a rough and very partial indi-
cation of the potential benefits of U.S. leadership in tobacco, the Task 
Force has projected the expected increase in lung cancer deaths in the 
forty-nine U.S. priority countries by 2025 and the increase that would 
exist if those countries made improvements at the same rate that the 
average high-income country did between 2000 and 2013 (Figure 
20). The difference between those projections just for lung cancer in 
these countries is 80,464 premature deaths and 135,831 deaths overall. 
Tobacco use and secondhand smoke are also leading risk factors for 
nearly all the NCDs identified by this Task Force as short- and near-
term priorities.
FIGURE 20:  PROJECTED PREMATURE LUNG CANCER DE AT HS I N 
U.S .  PR IOR I T y COUN TR I E S,  2014–2025
Underlying Data Source: Institute for Health Metrics and Evaluation, Global Burden of Disease Study 2013.
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lI veR CanCeR
The hepatitis B virus (HBV) is transmitted through bodily fluids and 
attacks the liver, causing chronic disease.156 It is the source of most cases 
of liver cancer and each year is responsible for five hundred thousand 
deaths globally. In low- and middle-income countries, most hepatitis 
B transmission occurs early, from mother to infant.157 The prevalence 
of this virus is greater and increasing in low- and middle-income coun-
tries, especially in sub-Saharan Africa and East Asia (Figure 21).
availability of ProvEn intErvEntions
A safe and highly effective HBV vaccine is cheap and widely used.158 
The complete series of the HBV vaccine provides twenty years, and 
possibly lifelong, protection in infants, children, and young adults.159 
HBV vaccination is also the most effective means of reducing the risk of 
liver cancer from aflatoxin, a carcinogenic byproduct of fungi on grains 
and other crops common in tropical countries with poor food safety 
FIGURE 21:  CHANGE I N PREMATURE LI VER CANCER DE AT HS I N 
U.S .  PR IOR I T y COUN TR I E S,  1990–2013
Data Source: Institute for Health Metrics and Evaluation, Global Burden of Disease Study 2013.
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regimes.160 A three-dose series of this vaccine costs less than two dol-
lars through UNICEF and is eligible for subsidy by the GAVI Alliance. 
Although 179 of 193 WHO member states have introduced HBV vac-
cine into their immunization programs, coverage is suboptimal—an 
estimated 75 percent.161 Many infants in sub-Saharan Africa and South 
Asia do not receive the first dose within twenty-four hours after birth, 
as needed.162
what thE unitEd statEs has to offEr
The countries in which children are not vaccinated for HBV are gen-
erally those with inadequate immunization programs. This Task Force 
recommends providing more technical and financial support for those 
child immunization programs; leveraging existing U.S. maternal and 
child health platforms to do so would help. This strategy may also yield 
compound benefits for controlling communicable diseases. Work-
ing with suppliers to package HBV vaccine in prefilled, auto-disable 
syringes appropriate for use in low-income countries would enable 
community-based health providers to deliver immunizations after 
home births, reducing the demand for health-care infrastructure in the 
poorest settings.163 
availablE cost EstimatEs
Universal immunization with the HBV vaccine is cost-effective. Even 
at twice its current two-dollar price, the Disease Control Priority Net-
work estimates that raising HBV immunization rates by another 25 per-
cent would cost $122 million annually, save six hundred thousand lives 
annually, and generate a return on investment at a ratio of ten-to-one 
from reduced death and disability.164 The Task Force’s recommenda-
tion would cost considerably less but would help raise the priority of 
HBV vaccination in low-income countries and improve coverage rates.
PotEntial imPact
Most vaccine-preventable diseases result in death at an early age, but 
deaths from liver cancer caused by hepatitis B happen years into the 
future. Countries that introduce hepatitis B vaccination today will 
experience significant benefits, but not for some time.165 Ten years is 
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too short a period in which to exhibit the full health gains. Neverthe-
less, as a rough indication of the potential benefits of U.S. leadership 
in the area, the Task Force has projected the expected increase in liver 
cancer deaths in the forty-nine U.S. priority countries by 2025 and the 
increase that would exist if those countries made improvements at the 
same rate that the average high-income country did between 2000 and 
2013 (Figure 22). The difference between those projections is 93,187 pre-
mature deaths and 230,090 deaths overall. 
FIGURE 22:  PROJECTED PREMATURE LI VER CANCER DE AT HS I N 
U.S .  PR IOR I T y COUN TR I E S,  2014–2025
Underlying Data Source: Institute for Health Metrics and Evaluation, Global Burden of Disease Study 2013.
CeRvICal CanCeR
Approximately three hundred thousand women die from cervical 
cancer each year, mostly young women in low- and middle-income 
countries. Cervical cancer is now the leading cause of death from cancer 
among women in sub-Saharan Africa and is a persistent, rising health 
challenge in the developing countries where the United States has other 
investments (Figure 23).
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A century ago, cervical cancer was as common in the United States 
as it is today in low- and middle-income countries. Screening to identify 
cancerous lesions and advances in effective treatment produced a steep 
decline in cervical cancer incidence and mortality in the United States 
and other high-income countries.166
availability of ProvEn intErvEntions
Most cervical cancer is caused by persistent infection with one of sev-
eral strains of HPV. Two interventions could transform cervical cancer 
control in low- and middle-income countries: increased access to the 
effective vaccines that exist for preventing HPV infection; and imple-
mentation of screening methods that are more compatible with the 
available resources and infrastructure in developing countries than Pap 
smear programs.
Two HPV vaccines exist, and they are safe and highly effective in 
women aged thirteen to twenty-six. These vaccines require three doses 
over six months and have been proven to remain effective for at least 
FIGURE 23:  CHANGE I N PREMATURE CERVICAL CANCER DE AT HS 
I N U.S .  PR IOR I T y COUN TR I E S,  1990–2013
Data Source: Institute for Health Metrics and Evaluation, Global Burden of Disease Study 2013.
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five years when all doses are given, although the protective period may 
be longer.167 The WHO has prequalified these vaccines, and they have 
also been approved for use by regulatory authorities in more than one 
hundred countries. 
In 2012, the GAVI Alliance announced it would help support access to 
a sustainable supply of HPV vaccines at a price of $4.50 per dose in the 
poorest countries and fund demonstration programs. Countries intro-
ducing HPV vaccines must meet GAVI’s co-financing requirement.168 
These same vaccines cost more than a hundred dollars per dose in high-
income countries; the lowest reported public-sector price for develop-
ing countries that are not poor enough to qualify for GAVI support is 
thirteen dollars per dose. 
A recent study found that most of the countries in which HPV vacci-
nation would prevent the greatest number of cervical cancers are in sub-
Saharan Africa, South Asia, and parts of Latin America, but that few 
have national HPV vaccination programs.169 One exception is Rwanda, 
which reported vaccinating more than 93 percent of its adolescent 
girls against HPV in 2013—a spectacular achievement that proves HPV 
immunization can work in low-income settings.170 
For women older than twenty-six, HPV vaccines cannot help. Cost-
effective screening and treatment programs for precancerous lesions 
using direct visualization and cryotherapy—or, when those are not suit-
able, the loop electrosurgical excision procedure (LEEP)—have been 
piloted in low- and middle-income countries with good results.171 Cer-
vical screening should start when a woman is in her thirties and occur at 
least once or twice in her lifetime.172
what thE unitEd statEs has to offEr
Co-financing a national HPV vaccination program is a challenge 
for many low- and middle-income countries. Leaving aside the still-
high price per dose, the vaccine must be delivered to a different age 
group than those who receive childhood immunizations and therefore 
requires development of new delivery programs. The nonprofit global 
health organization PATH has worked with low- and middle-income 
countries’ governments to assess HPV vaccination and found that 
delivery costs average one to four dollars per dose.173 These additional 
costs make the investment in HPV vaccination a difficult decision for 
these governments.
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The United States should help by increasing assistance to low- and 
middle-income countries seeking to lower HPV vaccine delivery costs 
and improve efficiency. It should also evaluate the opportunities and 
feasibility of leveraging existing U.S. platforms in health, development, 
and education. These platforms could help reduce the barriers to intro-
ducing and scaling the rollout of the HPV vaccine.174
The Task Force recommends that the United States increase its 
investment in improving and integrating low-technology screen-and-
treat programs for cervical cancer into PEPFAR platforms, building 
on the lessons of the successful Zambia pilot.175 There are other good 
examples of cervical cancer screening programs using nurses or mid-
wives in sub-Saharan Africa that the United States should evaluate.176 
The Pink Ribbon Red Ribbon initiative has been, and should continue 
to be, a good partner for the U.S. government in this area. 
availablE cost EstimatEs
A recent comprehensive study rated HPV vaccination, under current 
cost assumptions, as “very cost-effective” in 87 percent of the 179 coun-
tries assessed under the standard metrics for medical interventions.177 
HPV vaccination was rated as “very cost-effective” in all but two of the 
forty-nine U.S. priority countries and as “cost-effective” in the others 
(Jordan and Yemen).178 The WHO has developed a tool that countries 
and donors can use to estimate the costs of introducing the HPV vac-
cine to specific regions or nationally, the total cost per HPV vaccine 
dose, and the total cost per fully immunized girl.179
PotEntial imPact
Cervical cancer is increasingly becoming a health threat experienced 
only by poor women in poor countries. With increased U.S. leader-
ship, more may be done to help local governments address the needs 
of this underserved population. As with tobacco control and HBV vac-
cination, the returns of cervical cancer screening and vaccination are 
enormous but often only apparent in the long term. Nevertheless, as a 
very rough indication of the potential benefits of U.S. engagement, the 
Task Force has projected the expected increase in cervical cancer deaths 
in the forty-nine U.S. priority countries by 2025 and the increase that 
would exist if those countries improved at the same rate that the average 
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high-income country did between 2000 and 2013 (Figure 24). The dif-
ference between those projections would be 48,865 premature deaths 
and 118,802 deaths overall. 
FIGURE 24:  PROJECTED PREMATURE CERVICAL CANCER DE AT HS 
I N U.S .  PR IOR I T y COUN TR I E S,  2014–2025
Underlying Data Source: Institute for Health Metrics and Evaluation, Global Burden of Disease Study 2013.
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The Task Force has identified several NCD challenges for which 
effective interventions are widely used in the United States and other 
high-income countries but are not yet sufficiently low-cost or usable 
in low-infrastructure settings. Each challenge is especially prevalent 
among working-age populations in low- and middle-income coun-
tries where the United States has existing platforms that provide the 
opportunity for action. With U.S. leadership, more population and 
implementation research, and collaboration with private-sector and 
philanthropic partners, progress on adapting these interventions for 
cost-effective, low-infrastructure use is foreseeable in the near term.180
tRe atable anD CURable CanCeR S
Tremendous progress has occurred in the United States and other 
high-income countries toward preventing and treating many cancers. 
Mammography screening, endocrine treatment, discovery of biomark-
ers, and systemic chemotherapy have reduced U.S. breast cancer death 
rates by one-third between 1990 and 2014, mostly in younger women.181 
A large proportion of cancers affecting children and young adults are 
now also highly curable in high-income countries, in particular leuke-
mia and lymphomas, retinoblastoma, and testicular cancer.182 Screen-
ing tests for Helicobacter pylori—a bacterium associated with stomach 
cancer—and treatment with antibiotics have helped cut stomach cancer 
death rates in high-income countries by 20 percent over twenty years.183 
Although these cancers are treatable, curable, and declining in high-
income countries, they are increasing and causing substantial suffering 
in poor countries. Between 1990 and 2013, premature deaths in low-
income countries from breast cancer and leukemia grew 90 percent 
NCD Challenges on Which  
U.S. Leadership Would Make a Difference 
in the Near Term
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FIGURE 25:  CHANGE I N PREMATURE BRE A ST CANCER DE AT HS 
I N U.S .  PR IOR I T y COUN TR I E S,  1990–2013
Data Source: Institute for Health Metrics and Evaluation, Global Burden of Disease Study 2013.
and 25 percent, respectively.184 Similar patterns are seen in the coun-
tries where the United States has significant global health investments 
(Figures 25 and 26).
The reason for this disparity is that people in poor countries have 
little access to the diagnostic and curative care that is widely available for 
breast cancer and leukemia in wealthier countries. The per capita cost 
of mammography screening exceeds the capacity of many low-income 
countries to pay and may not be appropriate for settings wherein women 
often present with easily palpable, visible, or ulcerated tumors.185 
Appropriate breast cancer treatment depends on an accurate pathol-
ogy diagnosis, which in turn requires the availability of tissue sampling 
procedures. Chemotherapy and radiotherapy are available on a limited 
basis in middle-income countries, but often not in poorer nations. 
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FIGURE 26:  CHANGE I N PREMATURE LEUKEM IA DE AT HS I N U.S . 
PR IOR I T y COUN TR I E S,  1990–2013
Data Source: Institute for Health Metrics and Evaluation, Global Burden of Disease Study 2013.
PotEntial intErvEntions
There are at least four ways that the United States may assist low- and 
lower-middle-income countries in addressing breast cancer, leukemia, 
and other treatable or curable cancers. 
First, this Task Force recommends that the United States devote 
more resources to supporting registries in developing countries. Reli-
able, population-based registries define the incidence, mortality, and 
survival rates of different types of cancers and are fundamental to the 
development of local and national plans for improving cancer pre-
vention and treatment.186 The International Agency for Research on 
Cancer (IARC), the WHO, and others recently finalized standard-
ized guidelines for the planning and development of population-based 
cancer registries in developing countries.187 This is an important first 
step, but more is needed to support IARC in establishing regional hubs 
to provide training and technical assistance in setting up registries. NCI 
has important programs in these areas, but they are limited relative to 
the high demand.
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Second, the Task Force calls on U.S. leadership to help mobilize sup-
port for development of resource-level-appropriate guidelines for the 
management of treatable and curable cancers. Breast cancer provides a 
good model. With the support of the Susan G. Komen Foundation and 
NCI, the Breast Health Global Initiative was formed and has since pro-
duced a comprehensive set of resource-specific, stage-specific guide-
lines for breast cancer management.188 These guidelines provide the 
basis for prioritizing scarce local government resources and the blue-
print for future investments. Similar guidelines are needed for leukemia 
and other treatable and curable cancers.
Third, the Task Force finds that more U.S. support is needed for 
research and NGOs such as PATH that are working to lower the costs 
and infrastructure demands of breast cancer screening and diagnosis. 
Examples of promising approaches are community-based breast cancer 
screening models and frugal diagnostic technologies, such as cheaper 
and easier-to-use core-needle devices.189
Fourth, the Task Force believes the United States should explore 
avenues for increasing “telepathology” programs between U.S. public 
hospitals and developing countries. These programs have been suc-
cessfully used to build specialist capacity in Tanzania and Rwanda and 
create links with U.S. and European hospitals. More are needed.
Through these and other initiatives, the United States can help low- 
and middle-income countries build the foundation for addressing cur-
able and treatable cancers. The greatest impact on mortality would 
come from earlier detection, more accurate diagnosis, and more widely 
available basic treatment. The potential benefits are significant. For 
example, the Task Force has estimated the current projected increase 
in premature death rates in the forty-nine U.S. priority countries by 
2025 and the increase that would exist if those countries improved at the 
same rate that the average high-income country did between 2000 and 
2013 (Figure 27). The difference is 110,617 premature deaths and 173,672 
deaths overall. 
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DIabete S
Diabetes presents a special challenge in the Task Force’s recommended 
strategy for stemming the rising tide of NCDs in low- and middle-income 
countries. On treatment, it offers a similar investment case as cardiovas-
cular disease. There are also low-cost, long-off-patent medications for 
diabetes control. Metformin and insulin have existed since the1920s. Pro-
grams to monitor blood glucose levels and manage diabetes have been 
successfully integrated with HIV/AIDS and hypertension programs in 
Cambodia and can be piloted elsewhere.190 Diabetes is a rising health 
challenge in the same countries where the United States has significant 
global health investments (Figure 28). Premature deaths from diabetes in 
these countries increased 82 percent between 1990 and 2013. 
The challenge that diabetes presents is that, unlike with cardiovascu-
lar disease, the widespread availability of effective diabetes treatments 
and blood glucose monitoring has not sparked a dramatic decline in 
premature mortality in high-income countries. Under-age-sixty deaths 
FIGURE 27:  PROJECTED PREMATURE BRE A ST CANCER DE AT HS I N 
U.S .  PR IOR I T y COUN TR I E S,  2014–2025
Underlying Data Source: Institute for Health Metrics and Evaluation, Global Burden of Disease Study 2013.
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from diabetes increased 14 percent between 2000 and 2013 in high-
income countries, which already had a high disease burden. The reason 
is the spectacular increases in the prevalence of the disease and its 
underlying risk factors—obesity, physical inactivity, excessive alcohol 
consumption, high salt intake, and others. Although the rates of these 
risk factors are lower in most developing countries, particularly relative 
to the United States, they are nonetheless increasing. 
PotEntial intErvEntions
The Task Force recommends that the United States evaluate, pilot, and 
consider integrating diabetes objectives into hypertension procure-
ment, management, and registries. There is also an important need to 
explore interventions on juvenile diabetes. Deaths from this disease are 
rare in high-income countries, but are believed to be high in low-income 
countries where treatment and blood glucose monitoring programs are 
unavailable. These strategies have the potential to slow the increasing 
rate of premature mortality from diabetes and save a significant number 
of lives (Figure 29).
FIGURE 28:  CHANGE I N PREMATURE DIABE TE S DE AT HS I N U.S . 
PR IOR I T y COUN TR I E S,  1990–2013
Data Source: Institute for Health Metrics and Evaluation, Global Burden of Disease Study 2013.
69U.S. Leadership Would Make a Difference in the Near Term
Over the long term, it will be difficult to make progress in reducing 
the premature deaths and disability from diabetes without more effec-
tive population-based prevention and nutrition programs. These are 
challenges that the United States shares and are some of the topics dis-
cussed in the final section of this report.
FIGURE 29:  PROJECTED PREMATURE DIABE TE S DE AT HS I N U.S . 
PR IOR I T y COUN TR I E S,  2014–2025
Underlying Data Source: Institute for Health Metrics and Evaluation, Global Burden of Disease Study 2013.
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There are many NCD challenges for which no effective interventions 
yet exist in developed or developing countries. These are the areas 
wherein closer collaboration between the United States, developing 
countries, and private-sector partners would have the greatest benefits.
De velopI ng - anD emeRgI ng -CoUn tRY 
paRtneR S
There is no long-term treatment solution to the challenge of NCDs. 
Only prevention can reduce the burden of these diseases and lower their 
associated health-care costs to sustainable levels. This is true for the 
United States, but particularly so for developing countries with limited 
resources. The targets of NCD prevention are well known: salt intake, 
obesity, physical inactivity, excessive alcohol consumption, poor nutri-
tion, consumption of trans fats, and indoor air pollution. The strate-
gies for addressing those challenges are less established, at least not in a 
manner that can be applied cost-effectively, at the population level, and 
across different settings.
The United States and developing countries may have much to 
learn from each other on prevention. The United States may finally 
be making progress on its enormous childhood obesity problem, 
although that remains hotly debated.191 If it is, however, it would be 
the first (albeit tentative) sign of an effective anti-obesity campaign. 
Few population-based campaigns to increase physical activity have 
succeeded, but Brazil and Colombia have conducted initiatives that 
achieved positive results.192 
Nutrition is another promising area for collaboration between 
developed and developing countries on prevention. Many vegetables 
and fruits are disappearing from diets globally. More and more people 
Shared NCD Challenges  
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are subsisting on fewer and fewer crops.193 Inadequate access to fruits 
and vegetables is associated with diabetes, heart disease, and certain 
cancers and results in a surprisingly high number of deaths around the 
world (2.7 million annually).194 Low- and middle-income countries 
are leading initiatives, in some cases with U.S. funding, to incentivize 
smallholder farm production, promote urban gardens, and integrate 
nutrition and healthy diet promotion into primary care.195 If suc-
cessful, the approaches pioneered in countries such as Ethiopia and 
Honduras might also have relevance in the United States and other 
high-income countries.196 
As far as treatment is concerned, developing countries lead the way 
in experimenting with lower-cost chronic care models. Identification 
and scale-up of affordable NCD prevention and treatments of NCDs in 
these settings may help slow the spectacular rise of health costs in the 
United States and other developed countries.197 One area of particu-
lar need is mental health.198 Without an adequate mental health–care 
component, initiatives to address NCDs are more costly and less effec-
tive.199 The WHO estimates that nearly two hundred million people 
worldwide suffer from depression or schizophrenia, making the condi-
tions a leading cause of disability globally.200 Sufferers of mental illness 
are twice as likely to smoke cigarettes, more apt to be obese, and more 
likely to have multiple NCDs.201 Individuals with three or more NCDs 
generate more than 80 percent of U.S. Medicare costs.202 
Effective and affordable models of mental health care exist. Ran-
domized clinical trials in the United States have shown that integrating 
treatment into primary care improves the quality and outcomes of that 
care.203 Ethiopia, India, Nepal, South Africa, and Uganda have piloted 
basic mental health treatment packages, including offering access via 
their primary-care platforms to some or all of the medications on the 
WHO essential drug list.204 More research is needed to examine how to 
best train health workers, reduce stigma, and build public support for 
effective implementation of such programs in low-resource settings in 
developed and developing countries.
This Task Force recommends that the United States propose adding 
NCD prevention, diagnosis, and treatment to the agendas of its regular 
bilateral dialogues with Brazil, China, India, and Indonesia.205 These 
dialogues occur annually and provide a framework for building trust, 
constructive engagement, and collaboration on issues of shared stra-
tegic and economic interest. Past agendas for these dialogues have 
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included clean energy and promoting scientific collaboration.206 The 
premature and preventable burden of NCDs is enormous in these 
emerging nations, and an important issue for collaboration with the 
United States. 
pR I vate -SeCtoR paRtneR S
The role for the business community in addressing NCDs in low- and 
middle-income countries is threefold. First, many companies have 
natural concerns about maintaining the health and productivity of 
their workforces and the size and purchasing power of their customer 
bases. A 2010 World Economic Forum survey revealed that executives 
operating in South Asia and low-income countries had expressed the 
greatest concerns about the rise of NCDs.207 Many of these executives’ 
companies are leading the way in designing and implementing innova-
tive health promotion programs for their employees that emphasize 
exercise, preventive care, better diets, and reduced smoking. These pro-
grams may prove transferrable to broader populations.
Second, voluntary programs and partnerships with food and bev-
erage suppliers and retailers will be critical for progress on a number 
of NCD risk factors. Many developing-country governments lack the 
capacity and popular support for implementing tax and regulatory 
measures to change diets. The UK Food Standards Agency reduced 
salt intake by 15 percent, primarily through voluntary agreements with 
manufacturers to reformulate products.208 Such agreements are prov-
ing far more effective than attempts to inspire population-level behav-
ior change in individual cooking and eating habits.209 More voluntary 
and independently audited agreements are needed to lower salt intake 
in other countries as well as to reduce trans fats, unhealthy oils, sugars, 
and the marketing of unhealthy food and beverages to children. These 
negotiations should be coordinated by regional health authorities, be 
facilitated by the U.S. development agencies, and involve leaders from 
the public health community and manufacturers and retailers.
Third, the private sector is best suited to invent and adapt technolo-
gies for NCD prevention and treatment in low-infrastructure settings. 
Pharmaceutical, medical device, and information technology compa-
nies can develop and distribute effective and affordable diagnostics, 
therapies, and information systems needed to lower NCD prevention, 
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detection, and treatment costs. Frugal technologies developed for 
low-income settings may prove popular for high-income-country use. 
General Electric (GE) has made this approach, known as reverse inno-
vation, a core part of its health-care business model.210 GE developed 
a portable electrocardiographic diagnostic tool for India that costs 
one-fifth of the price of the high-income-country model. This por-
table electrocardiogram is now reportedly popular among German 
primary-care physicians.211 
The Task Force has identified three areas in which further innova-
tion and private-sector participation are needed: clean cookstoves, 
breast cancer diagnostics, and the use of information and communica-
tion technologies (eHealth) and mobile phones (mHealth) to support 
NCD prevention and management.
Indoor air pollution is among the top five health risks for developing 
countries and a particular challenge for women who do most of the meal 
preparation in these settings. The WHO estimates that three billion 
people cook and heat their homes using open fires and simple stoves, 
burning biomass (wood, animal dung, and crop waste) and coal.212 The 
Global Alliance for Clean Cookstoves is doing good work, but gener-
ating cleaner, low-cost stoves that respond to local needs, tastes, and 
customs is difficult. More private-sector engagement and innovative 
partnerships with developing country entrepreneurs might help. 
Mammography screening is still too expensive and resource-inten-
sive for widespread use in many developing countries to address rising 
breast cancer rates. Clinical breast examinations might help if cheaper 
diagnostic technologies were available that could be used by nurses and 
other lower-skilled health workers. With radiotherapy and chemother-
apy unavailable in many low- and middle-income countries, mastecto-
mies would remain the best treatment option, but they are only effective 
with early and accurate diagnosis.213 
Despite the intuitive appeal of cell phones as a low-cost way to reach 
large numbers of people in low-infrastructure settings, the early results 
of eHealth and mHealth initiatives are not encouraging.214 Further 
innovation is needed, and the private sector is likely to be best suited to 
succeed in this area.
This Task Force recommends that the U.S. government act as a 
convener of multinational corporations and NGOs working to apply 
and adapt cost-effective technology for NCDs in low-infrastructure 
developing-country settings. The purpose would be to coordinate and 
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scale private-sector creativity and assets around critical NCD-related 
needs for which the market potential is not yet realized. The White 
House, Department of State, and USAID have hosted similar efforts 
on global health and international development, but those meet-
ings did not address NCDs or their risk factors.215 USAID should 
also incorporate NCDs into its Grand Challenges program, which 
leverages outside funding to support research on U.S. development 
priorities, and the Development Innovation Ventures fund, which 
provides seed capital to high-risk, high-return, development-friendly 
technologies.216
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Global health is in transition. The exotic parasites, bacterial blights, 
and communicable diseases that have long occupied international 
health initiatives remain important but are declining in most countries. 
That is good news, but this epidemiological transition is not yielding 
the demographic and economic benefits that accompanied that transi-
tion in wealthier countries. Cancers, heart disease, and other NCDs 
are increasing in prevalence faster, arising in younger populations, and 
having worse outcomes than in wealthy nations. Unless urgent action is 
taken, this emerging global health crisis will worsen and become harder 
to address. 
Just as low- and middle-income governments must adapt and retool 
to confront their changing health demands, so too must the United 
States and other international actors that have invested in global health. 
It is not sustainable to continue to invest billions fighting treatable and 
preventable diseases only to watch the same patients perish prema-
turely as a result of equally treatable and preventable conditions, and in 
increasing numbers. This is especially true for those NCDs for which 
many premature deaths are avoidable with relatively low cost. 
U.S. interests in addressing HIV/AIDS, malaria, and poor repro-
ductive and maternal health lay not in these diseases and conditions 
themselves, but in the well-being and fortunes of the countries and 
working-age people that suffer from them. The same interests exist 
with NCDs. As the scale and consequence of this NCD epidemic 
grows rapidly in low- and middle-income countries, so will the threat 
to U.S. interests. 
This Task Force is under no illusion that the recommendations and 
strategies outlined in this report are alone sufficient to stem the tide 
of NCDs in developing countries. Building health systems, allocating 
scarce resources, and enforcing public health laws and consumer pro-
tections are decisions for national governments alone. Yet the priorities 
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of the United States and global health actors deeply influence those 
decisions. The recommendations and strategies outlined in this report 
would save lives, demonstrate the feasibility of progress on NCDs, and 
catalyze broader action. The time to act is now.
This Task Force recommends two immediate steps. First, the U.S. 
government must undertake a serious examination of its current global 
health priorities and spending and act to ensure their continued effec-
tiveness in advancing U.S. interests. That examination should consider 
the potential for additional funds and the feasibility of expanding the 
mandate of U.S. programs from disease-focused objectives to more 
outcome-oriented measures for improving the health of the popula-
tions targeted. 
Second, the United States should convene the leading actors and 
potential partners on addressing NCDs—national governments; 
intergovernmental and international institutions such as the WHO, 
World Bank, Global Fund, and GAVI Alliance; philanthropic foun-
dations and NGOs; and private companies, especially large-scale 
employers operating in low- and middle-income countries. If the 
United States devoted resources to addressing NCDs in similar 
amounts as it spends on other global health priorities ($236 million 
on TB in FY 2014), it would go a long way toward implementing the 
recommendations outlined in this report.217 Those costs, however, 
should not be borne by the United States alone. The purpose of this 
convening should be to develop a practical, well-prioritized, and sus-
tainable plan for collective action on the emerging global health crisis 
of NCDs in low- and middle-income countries. 
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The Task Force report does an excellent job outlining the challenges and 
some of the strategies dealing with noncommunicable diseases in the 
developing world, and for that reason I endorse it.
But the report does not fully include diet, nutrition, and other forms 
of preventative care as key strategies to help stem the tide of diabetes, 
cardiac problems, hypertension, cancers, and other medical conditions. 
The report does mention that nutrition is a promising area for collabora-
tion between developed and developing countries on prevention. Inad-
equate access to fruits and vegetables is associated with diabetes, heart 
disease, and certain cancers and results in a surprising high number of 
deaths around the world. And the report does indicate that “dietary fac-
tors” are the single leading health risk in developing countries. Yet the 
report gives short shrift to identifying public-health solutions and strat-
egies that directly address these dietary factors and nutritional defi-
ciencies, especially in ensuring balanced diets in the developing world. 
In recent years, many organizations, including the UN’s World Food 
Programme, the U.S. Agency for International Development, the U.S. 
Departments of Agriculture and Health and Human Services, as well 
as various NGOs, foundations, and private sector companies have all 
identified poor nutrition as a leading factor in child stunting and other 
diseases, including adult-onset diabetes and cancer. The evidence is 
legion that poor nutrition and an unbalanced diet are major contribu-
tors to these diseases, and good diets have a particularly important role 
in buttressing immune systems. In the same way that the report under-
scores the importance of reducing tobacco consumption, hypertension, 
and cancer rates, as well as increasing access to modern medicines, we 
also need to highlight strategies that better integrate food and nutrition, 
as well as improved food and water safety, into our more traditional 
clinical strategies, and consider them a key part of the total picture.
Additional Views
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The basic health-care infrastructure of the developing world needs 
holistic solutions to deal with these noncommunicable diseases, which 
include the strategies contained in the report, modern medicine, good 
sanitation, and adequate and balanced food intake. Modern medicine 
has been outstanding in working on cures for diseases, but in my judg-
ment the medical community has not given the same attention to pre-
vention as a way to deal with disease. That includes diet and nutrition. 
As the French author Anthelme Brillat-Savarin wrote nearly two hun-
dred years ago, “Tell me what you eat, and I will tell you what you are.” 
Or in more colloquial terms, you are what you eat. A huge part of our 
effort to prevent disease and extend life should be rooted in that histori-
cal quotation.
Daniel R. Glickman
The Task Force report provides an important perspective and call to 
action to address NCDs in the most hard-hit and at-risk countries 
around the globe. The report accurately and rightfully acknowledges 
the critical toll NCDs are taking on political, social, and health sys-
tems in many countries. The challenges to preventing and treating 
NCDs are exacerbated in many of these countries because of under-
resourced and underfunded health systems. Innovative and proactive 
programs must be implemented in the immediate term to help sur-
mount the growing morbidity and mortality from NCDs in resource-
limited settings. 
The report articulates the perspective of U.S. interests and thus the 
incentives to help lead efforts to tackle this disease burden. Understand-
ably, it is important to provide compelling reasons and to galvanize 
U.S. policymakers and spending authority to invest in the effort against 
NCDs; it is required to mobilize the needed support from the United 
States, a leader in global health. However, I would stress that the solu-
tions—the actual programs, the policies, and final spending allocations 
towards particular NCDs—be done in close consultation and following 
the lead of host national governments. This approach will help ensure 
local buy-in and participation in solutions, which will increase their like-
lihood to succeed. For example, the report cites the success of Rwanda’s 
HPV vaccination program. This success is in large part because it was 
a national priority instigated by the ministry and thus implemented in 
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an embraceable and scalable manner. This country-led approach often 
requires patience and flexibility, but it is also often more efficient and 
effective in the long run.218
Vanessa Kerry
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